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“What is a scientist after all? 
It is a curious man looking through a keyhole, 
the keyhole of nature, trying to know what’s going on.”
       Jacques-Yves Cousteau 
       (oceanographer, 1910-1997)
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ACE and Atherosclerosis
Atherosclerosis literally means “hardening of blood vessels”. It is a form of 
progressive pathology of large arteries, characterised by the accumulation  
of lipids and fibrous tissue in vessel walls. These changes alter both the 
structure (the thickness of the wall) and the function (elasticity) of the 
arteries. Atherosclerotic lesions can grow over time, and, in the long run, 
may lead to blocks in blood flow. Another clinical complication is an acute 
occlusion due to the formation of a thrombus or blood clot, resulting in 
myocardial infarction, stroke, or other end organ damages. These diseases 
are the most important causes of morbidity and are responsible for 50% of 
all mortality in the United States, Europe and much of Asia.1 
Alterations in the structure and function of arterial walls can be measured 
in different ways. Non-invasive techniques are the most frequently applied 
methods to studies in populations at large. In the studies presented in this 
thesis, we used carotid artery intima media thickness (IMT) and plaque 
score as measurements of atherosclerosis. In addition, we also investigated 
arterial stiffness using carotid distensibility and carotid-femoral pulse wave 
velocity (PWV). Carotid IMT and plaque score mainly present changes in 
arterial wall thickness, while distensibility coefficient and PWV are measures 
of arterial stiffness. 
Epidemiological studies over the past 50 years have revealed numerous 
risk factors for atherosclerosis.2 Some of traditional risk factors are age, male 
gender, hyperlipidaemia, hypertension, diabetes, obesity, inflammation, a 
high-fat diet, smoking, and a lack of exercise. These factors can be grouped 
into those with important genetic components, and ones that are largely 
environmental in origin.
Genetics of atherosclerosis
The general, contribution of genetic factors to a disorder in a population 
can be assessed by heritability estimates, indicating what proportion of the 
variability of the disorder can be explained by genetic factors in a given 
population. Using different kinds of atherosclerosis measurements, many 
scientists investigated the heritability of atherosclerosis3-5 and showed that a 
substantial part of this disorder is under genetic influence. 
Discovering the specific genetic components of atherosclerosis, however, 
proved to be a challenging task. Numerous physiological pathways are involved 
in the establishment of vascular homeostasis. Genetic or environmental  
factors involved in one or more of those physiological pathways may  
contribute to the creation and progress of pathological status in the vascular 
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system. This makes atherosclerosis a typical complex trait. In this thesis, we 
focused on a single pathway, the renin angiotensin system.
Angiotensin converting enzyme gene and  
atherosclerosis
The renin angiotensin system is one of the important systems involved in 
cardiovascular homeostasis in which angiotensin converting enzyme (ACE) 
plays an important role by converting angiotensin I to angiotensin II.6 The 
effects of angiotensin II on the vascular system include systemic vasoconstriction, 
mediating cell growth and the proliferation of vascular smooth muscle cells by 
stimulating various cytokines and growth factors,7 and inducing endothelial 
dysfunction by reducing nitric oxide bioavailability.8 ACE, therefore, plays 
a central role in cardiovascular homeostasis and is considered to be important 
in the pathogenesis of atherosclerosis. 
ACE levels in plasma and tissue are under genetic control.9,10 The ACE 
gene is located on chromosome 17q23 and contains numerous polymorphisms. 
The identification, however, of which of these variants directly influence 
ACE concentrations is ambiguous because of the almost complete linkage 
disequilibrium present in the Caucasian population.11 The most frequently 
studied polymorphism is the presence (insertion, I) or absence (deletion, 
D) of a 287 bp alu repeat. Although located in the non-coding region of 
the gene (intron 16), it was one of the first available polymorphisms on this 
gene and received the attention of many researchers when it was reported 
that higher ACE plasma and tissue levels are present in subjects with the D 
allele compared with the ones carrying the I allele.9,10 
Scope of the thesis
We investigated the genetics of atherosclerosis utilizing the ACE gene as 
one of the candidate genes that influence vascular homeostasis and may be 
responsible for development of atherosclerosis and possibly later clinical  
cardiovascular outcomes. Chapter 2 provides an overview of the contribution 
of genetic factors to the function and structure of the arterial wall. This 
study is based on the ongoing Erasmus Rucphen Family (ERF) study, based 
in an isolated population in The Netherlands. Using a single pedigree, we 
estimated the heritability of carotid-femoral PWV, common carotid IMT, 
and carotid plaques. 
15
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In chapter 3, we examined the association between the ACE I/D  
polymorphism and atherosclerosis measurements. We first evaluated the 
relation between this polymorphism and carotid IMT by means of a meta-
analysis (chapter 3.1). Then, we investigated the same association in the 
Rotterdam Study, a population based cohort study among subjects aged 55 
years or older (chapter 3.2). Finally, we examined the relationship between 
the I/D polymorphism and arterial stiffness using carotid distensibility and 
carotid-femoral PWV (chapter 3.3). 
In chapter 4, the association between the ACE I/D polymorphism and 
clinical outcomes was investigated. We first looked at cardiovascular  
morbidity and mortality as the main outcomes (chapter 4.1). Next, we 
evaluated the same association considering total mortality as the outcome 
of interest (chapter 4.2). Finally, we tested the hypothesis of the co-morbidity  
effect of a single risk factor in relation to multiple outcomes by using the 
ACE I/D and risk of Alzheimer’s disease as an example (chapter 4.3). In 
chapter 5, a general discussion is presented to give a broader perspective of 
other studies on the ACE I/D polymorphism and to provide suggestions for 
future research. 
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Chapter 2 
Genetic contributions 
to atherosclerosis
Heritability of the function and structure of the arterial wall:  
the Erasmus Rucphen Family (ERF) study
18
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Abstract
Using 930 individuals connected in a single pedigree from an isolated population, 
participants of the Erasmus Rucphen Family (ERF) study, we investigated the 
heritability of carotid-femoral pulse wave velocity (PWV), carotid intima media 
thickness (IMT), and carotid plaque score. PWV was measured between the carotid 
and femoral arteries as an indicator of aortic stiffness. Common carotid IMT and 
plaque score, quantifying alterations in arterial wall structure, were measured 
by ultrasonography. All three traits were significantly associated with classical 
cardiovascular risk factors. Age and gender adjusted heritability estimates were 0.36 
for PWV, 0.41 for carotid IMT, and 0.28 for plaque score. After adjustment for 
appropriate risk factors, the heritabilities were 0.26, 0.35, and 0.21 for PWV, IMT, 
and plaque score, respectively. All heritability estimates were statistically significant 
(p < 0.001). Taking into account different proportions of variance associated with 
covariates for each trait, genetic factors explained approximately 12% of the total 
variability for each of the phenotypes. To our knowledge, this is the first report on 
the heritability of PWV. The heritability estimates of IMT and plaque score were 
similar to those in previous reports. We conclude that genetic factors significantly 
contribute to arterial structure and function in this isolated population, presenting 
the opportunity to locate susceptibility genes related to cardiovascular disorders. 
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Introduction
Arterial stiffness and atherosclerosis are major factors in pathophysiological 
pathways leading to various cardiovascular diseases. In western society, these 
diseases are the underlying cause of about 50% of all deaths.1 Stiffness of 
the arteries can be assessed by pulse wave velocity (PWV), a non-invasive  
measurement of arterial wall function. Aortic stiffness, as measured by 
carotid-femoral PWV, has been shown to be an independent predictor of 
cardiovascular morbidity and mortality in patients with essential  
hypertension2,3 and end-stage renal disease,4,5 and has been shown to be 
strongly associated with atherosclerosis at various sites in the vascular tree.6 
Carotid intima media thickness (IMT) has been used as a proxy for  
atherosclerosis. It has been shown to be correlated with atherosclerosis in 
other arterial sites7 and a strong predictor of myocardial infarction.8 In  
addition, quantitative assessment of plaques in carotid arterial walls can also 
be used as an indicator of atherosclerosis.9 
Genetic factors play a major role in alterations of arterial wall function 
and structure.10 Prior findings, however, on the extent to which genetic  
factors may explain the variance of these traits (heritability) are highly 
variable and limited in number. Heritability estimates (h2) of carotid IMT 
published thus far range widely from 0.21 to 0.92,11,12 but most of the 
studies reported heritabilities around 0.30 and 0.40.13-17 To our knowledge, 
only one study on the heritability of carotid plaques was performed,18 
yielding an estimate of 0.23, and no heritability estimate for PWV has been 
published to date. 
We studied the heritability of carotid-femoral PWV, carotid IMT, and 
carotid plaques in an extended pedigree from an isolated population in The 
Netherlands. 
 
Materials and methods
Study population
Subjects were participants of the Erasmus Rucphen Family (ERF) study. 
This is an ongoing large family based study, which began in June 2002  
in a genetically isolated population located in the southwest of The  
Netherlands. This population was founded in the middle of the 18th  
century by approximately 150 individuals and was isolated until the last 
few decades. It is characterised by rapid growth and minimal immigration 
and has now expanded to roughly 20,000 inhabitants. 
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For this population, an extensive genealogical database including over 
63,000 individuals is available. For the ERF study, 20 couples were selected 
that had at least six children baptised in the community church between 
1880 and 1900. All living descendants of the selected couples and their 
spouses (n ≈ 2500) were invited to participate in the study. The pedigree 
members were not selected based on any disease status. This study is based 
on the first 930 participants for whom complete phenotypic data were 
available at the time of the analyses. The Medical Ethics Committee of 
the Erasmus Medical Centre Rotterdam approved the study and informed 
consent was obtained from all participants. 
Data collection
At the research centre, located within the community, extensive clinical 
examinations were done, including the collection of fasting blood samples, 
anthropometric measurements, cardiovascular assessments, neurological 
tests, ophthalmologic examinations and personal interviews. The interviews 
were performed by medical practitioners and included questions on education  
level, smoking status, current medication use, and medical history.
Glucose, lipids, creatinine, and plasma albumin levels were measured 
from the fasting blood sample, according to standard procedures.19,20 
Height and weight were measured with the participant in light underclothing  
and body mass index (kg/m2) was computed. Blood pressure was measured 
twice on the right arm in a sitting position after at least five minutes rest, 
using an automated device (OMRON 711). The average of the two measures 
was used in the analyses. Mean arterial pressure (MAP) was calculated as 
1/3 systolic blood pressure + 2/3 diastolic blood pressure.
During the cardiovascular assessment, carotid-femoral pulse wave 
velocity (PWV) was measured by means of an automatic Complior® SP 
device with the subjects in a supine position. The time delay between the 
rapid upstroke of the feet of simultaneously recorded pulse waves in the 
carotid and the femoral arteries were assessed and the distance between the 
carotid and the femoral arteries was measured over the surface of the body 
with a tape measure. PWV was calculated as the ratio between the distance 
travelled by the pulse wave and the time delay, and expressed in meters 
per second. The Complior® SP device recorded the pulse waves during a 
10 second time frame and automatically calculated the mean PWV of the 
recorded pulses. 
A duplex scan ultrasonographic investigation of the carotid arteries 
was made using a 7.5 MHz linear array transducer (ATL, Ultramark IV). 
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A careful search was performed for the lumen-intima interface and the 
media-adventitia interface. Three optimal still images were recorded on the 
videotapes from each artery site (common carotid, bifurcation and internal 
carotid arteries at the right and left sides). Measurements of intima media 
thickness (IMT) were performed offline using the still images. The interfaces 
of the far and near wall of the distal common carotid artery are marked 
over a length of 10 mm. We used measurements of common carotid IMT 
in this study, which is calculated as the mean of the maximum IMT of the 
near and far wall measurements from both the left and right arteries. When 
a plaque was present at the 10 mm measurement site, IMT was measured at 
the region closest to the plaque. 
During the ultrasound, the common carotid artery, carotid bifurcation 
and internal carotid artery were also visualised over the longest segment 
possible in both the left and right sides for the presence of plaques. Plaques 
were defined as local widening of the arterial wall relative to the adjacent 
segment, with protrusion into the lumen. The total plaque score reflected 
the total number of sites with plaques and ranged from 0 to 12 (considering 
the far and near walls of the artery in each of the three different arterial sites 
on both the left and right sides). 
Statistical analyses
General characteristics were compared between men and women, using 
student t-test for continuous variables and chi-square test for dichotomous 
variables, with SPSS 11.0 for Windows. Inbreeding coefficients were  
calculated using the PEDIG software21 based on a pedigree of the total 
population. The inbreeding coefficient equals the probability that two  
identical alleles at a given locus in an individual are identical by descent 
(are copies of the same ancestral allele). This coefficient represents the  
degree of consanguinity between the parents of the individual. 
For the heritability analyses, we first performed univariable and multi-
variable regression analyses using SPSS. All covariates that were significant 
at the 0.10 level in the multivariable analysis were retained in the final 
model for heritability estimation. In order to obtain a normal distribution 
of the regression residuals for the traits under study, we used the natural 
logarithm transformation of (PWV – 3) and (IMT – 3). Since MAP is 
shown to strongly influence arterial stiffness,22 it was used instead of systolic 
and diastolic blood pressures in the analyses related to PWV. In the multi-
variable regression models for IMT and plaque score, the beta coefficient 
for diastolic blood pressure is reported from a model without systolic blood 
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pressure to avoid the multicolinearity effect. Both variables were used in the 
final analyses. 
A variance component maximum likelihood method implemented in 
the SOLAR 2.1.2 software package23 was used to partition the phenotypic 
variance of PWV, IMT, and plaque score into their additive genetic and 
environmental elements. The contribution of genetic factors to these traits 
was then estimated as the heritability, defined as the proportion of variance 
(after correction for covariates) explained by additive genetic components. 
Heritability estimates were calculated using a model with only age and 
gender and a full model with all significant covariates from the regression 
analyses to determine the extent genetic factors contribute to the variation 
in PWV, IMT, and plaque score, independent of the measured risk factors.  
We also presented the contribution of the genetic factors to the total variance  
of each trait in different models, calculated as: [(1 – proportion of variance 
explained by covariates) × heritability estimate]. Significance was determined 
by likelihood ratio tests. 
Table 1. Demographic characteristics of the study population
Variable Men (n = 376) Women (n = 554)
Age (years) 53.85 ± 13.71 51.05 ± 14.36*
Body mass index (kg/m2) 27.50 ± 4.06 26.70 ± 4.81*
Systolic BP (mmHg) 145.14 ± 20.24 138.93 ± 22.86*
Diastolic BP (mmHg) 82.25 ± 10.42 78.82 ± 9.66*
Mean arterial pressure (mmHg) 103.21 ± 12.34 98.86 ± 12.61*
LDL cholesterol (mmol/L) 3.73 ± 0.97 3.74 ± 1.04
HDL cholesterol (mmol/L) 1.13 ± 0.32 1.37 ± 0.36*
Triglycerides (mmol/L) 1.59 ± 1.02 1.29 ± 0.63*
Fasting glucose (mmol/L) 4.94 ± 1.05 4.63 ± 1.04*
Current smoking (%) 33.69 48.36*
No college education (%) 90.37 90.73
Inbreeding (%) 78.72 77.08
Pulse wave velocity (m/s) 10.55 ± 2.49 9.48 ± 2.06*
Common carotid IMT (mm×10–1) 9.15 ± 2.18 8.31 ± 1.92*
Continuous values are mean ± standard deviation. 
BP: blood pressure; HDL: high density lipoprotein; IMT: intima media thickness; 
LDL: low density lipoprotein. 
* p < 0.05 compared with men. 
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Results
The gender specific characteristics of the participants are shown in Table 1. 
All 930 participants were part of one extended pedigree. Men were, on 
average, three years older than women. Almost all of the established  
cardiovascular risk factors were higher in men, with the exception of low 
density lipoprotein (LDL) cholesterol, which showed no differences  
between genders, and current smoking, which was higher in women (Table 1). 
Table 2 shows the association between risk factors and PWV in univariable  
and multivariable models. In the univariable model, the association between 
gender and the outcome variables was adjusted for age, and the association 
between age and the outcomes was adjusted for gender. All other associations  
were adjusted for both age and gender. Only high density lipoprotein 
(HDL) cholesterol, smoking, low education, and inbreeding coefficient 
were not significantly related to PWV (Table 2). In the multivariable 
model, the only factors that significantly determined PWV were age,  
Table 2. Univariable and multivariable regression analyses of PWV*
Variable Univariable Multivariable
Beta ± SE p Beta ± SE p
Age (years) 0.014 ± 0.001 < 0.001 0.011 ± 0.001 < 0.001
Male gender 0.114 ± 0.017 < 0.001 0.079 ± 0.017 < 0.001
Body mass index (kg/m2) 0.004 ± 0.002 0.044 –0.001 ± 0.002 0.911
Mean arterial pressure (mmHg) 0.008 ± 0.001 < 0.001 0.007 ± 0.001 < 0.001
LDL cholesterol (mmol/L) –0.017 ± 0.008 0.035 –0.015 ± 0.008 0.049
HDL cholesterol (mmol/L) –0.037 ± 0.024 0.117 –0.025 ± 0.024 0.289
Triglycerides (mmol/L) 0.029 ± 0.010 0.004 0.007 ± 0.012 0.534
Fasting glucose (mmol/L) 0.027 ± 0.009 0.002 0.011 ± 0.008 0.176
Current smoking –0.010 ± 0.017 0.503 –0.003 ± 0.016 0.865
No college education –0.001 ± 0.028 0.989 –0.008 ± 0.027 0.776
Heart rate (beat/m) 0.001 ± 0.001 0.008 0.001 ± 0.001 0.057
Inbreeding coefficient –1.568 ± 1.232 0.203 –0.236 ± 1.181 0.842
In the univariable analyses all associations are adjusted for age and gender. The association 
between gender and PWV is adjusted for age, and the association between age and PWV is 
adjusted for gender. 
Beta: regression coefficient; HDL: high density lipoprotein; LDL: low density lipoprotein; 
PWV: pulse wave velocity; SE: standard error. 
* Natural logarithm transformation was performed to obtain a normal distribution of the residuals. 
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gender, MAP, LDL cholesterol, and heart rate. These factors were included 
in the multivariable adjusted model for the heritability analyses. Since fasting  
glucose levels have been associated with PWV,24 this variable was also  
included in the final model.
Table 3 presents the results of the univariable and multivariable  
regression analyses for IMT. The univariable model showed that all of the 
considered risk factors were significantly associated with IMT, excepting 
inbreeding coefficient. In the multivariable model, only triglycerides, low 
education, and inbreeding coefficient showed no significant association 
with IMT. For plaque score, diastolic blood pressure, triglycerides, glucose 
levels, low education, heart rate, and inbreeding coefficient were not  
significantly associated in the univariable model (Table 4). In the multivariable 
model, the significance level of the associations remained unchanged. 
The estimated components of variance for PWV, IMT, and plaque 
Table 3. Univariable and multivariable regression analyses of IMT*
Variable Univariable Multivariable
Beta ± SE p Beta ± SE p
Age (years) 0.019 ± 0.001 < 0.001 0.016 ± 0.001 < 0.001
Male gender 0.095 ± 0.015 < 0.001 0.070 ± 0.017 < 0.001
Body mass index (kg/m2) 0.007 ± 0.002 < 0.001 0.005 ± 0.002 0.016
Systolic BP (mmHg) 0.003 ± 0.001 < 0.001 0.004 ± 0.001 < 0.001
Diastolic BP (mmHg) 0.002 ± 0.001 0.023 0.002 ± 0.001† 0.052†
LDL cholesterol (mmol/L) 0.017 ± 0.007 0.021 0.020 ± 0.008 0.011
HDL cholesterol (mmol/L) –0.093 ± 0.021 < 0.001 –0.062 ± 0.024 0.009
Triglycerides (mmol/L) 0.024 ± 0.009 0.009 0.004 ± 0.012 0.760
Fasting glucose (mmol/L) 0.026 ± 0.007 0.001 0.014 ± 0.008 0.091
Current smoking 0.046 ± 0.015 0.002 0.049 ± 0.016 0.002
No college education 0.066 ± 0.026 0.012 0.032 ± 0.027 0.235
Heart rate (beat/m) –0.001 ± 0.001 0.012 –0.001 ± 0.001 0.015
Inbreeding coefficient –0.377 ± 1.092 0.730 –1.368 ± 1.174 0.244
In the univariable analyses all associations are adjusted for age and gender. The association between  
gender and IMT is adjusted for age, and the association between age and IMT is adjusted for 
gender. 
Beta: regression coefficient; BP: blood pressure; HDL: high density lipoprotein;  
IMT: intima media thickness; LDL: low density lipoprotein; SE: standard error. 
* Natural logarithm transformation was performed to obtain a normal distribution of the residuals. 
† Estimated from a multivariable model without systolic blood pressure.
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score are presented in Table 5. All estimates of heritability were statistically 
significant. Adjusted for age and gender, the heritability estimate was 0.36 
for PWV, indicating that the additive effects of genes account for 36% of 
the variation in PWV that is not explained by age and gender. With 0.45 of 
the variance being explained by age and gender, genetic factors account for 
[(1.0 – 0.45) × 0.36] ≈ 0.20 of the total variance in the PWV trait. After 
further adjustment for additional covariates, the estimate of heritability 
was 0.26, meaning that [(1.0 – 0.53) × 0.26] ≈ 0.12 of the total variance 
of the PWV trait is explained by genetic factors. For IMT, the heritability 
was 0.41 in the first model and 0.35 in the second models, suggesting that 
genetic factors explain ≈ 0.16 and ≈ 0.12 of the total variance of IMT in 
the first and the second model, respectively. Heritability estimates of plaque 
score were 0.28 and 0.21, corresponding to ≈ 0.17 and ≈ 0.12 of the total 
variance explained by genetic factors. 
Table 4. Univariable and multivariable regression analyses of plaque score
Variable Univariable Multivariable
Beta ± SE p Beta ± SE p
Age (years) 0.152 ± 0.006 < 0.001 0.130 ± 0.008 < 0.001
Male gender 0.767 ± 0.182 < 0.001 0.672 ± 0.206 0.001
Body mass index (kg/m2) –0.049 ± 0.020 0.015 –0.078 ± 0.023 0.001
Systolic BP (mmHg) 0.026 ± 0.005 < 0.001 0.040 ± 0.006 < 0.001
Diastolic BP (mmHg) –0.001 ± 0.009 0.994 0.010 ± 0.010* 0.317*
LDL cholesterol (mmol/L) 0.193 ± 0.090 0.031 0.238 ± 0.094 0.011
HDL cholesterol (mmol/L) –0.680 ± 0.261 0.009 –0.761 ± 0.287 0.008
Triglycerides (mmol/L) 0.147 ± 0.110 0.183 0.021 ± 0.140 0.882
Fasting glucose (mmol/L) –0.008 ± 0.089 0.926 0.075 ± 0.102 0.460
Current smoking 1.013 ± 0.180 < 0.001 0.839 ± 0.195 < 0.001
No college education 0.473 ± 0.317 0.136 0.012 ± 0.324 0.971
Heart rate (beat/m) –0.004 ± 0.005 0.390 –0.004 ± 0.005 0.346
Inbreeding coefficient 19.858 ± 13.244 0.134 15.769 ± 14.133 0.265
In the univariable analyses all associations are adjusted for age and gender. The association 
between gender and plaque score is adjusted for age, and the association between age and plaque 
score is adjusted for gender. 
Beta: regression coefficient; BP: blood pressure; HDL: high density lipoprotein; 
LDL: low density lipoprotein; SE: standard error. 
* Estimated from a multivariable model without systolic blood pressure. 
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Discussion
In this large family based study in an isolated population, we investigated 
the contribution of genetic and environmental factors to carotid-femoral 
pulse wave velocity, common carotid intima media thickness, and carotid 
plaque score. Our study indicated that after adjusting for age, gender, blood 
pressure, heart rate, plasma lipids, fasting glucose, body mass index, and 
smoking, when appropriate, the additive effects of genes explain significant 
proportions of the variability in the function and structure of the arterial 
wall in this population.
To our knowledge, the present study is the first to report on the  
heritability of pulse wave velocity, which mainly measures aortic stiffness. 
In the Rotterdam Study, we previously showed that arterial stiffness is 
strongly associated with common carotid intima media thickness, severity 
of plaques in the carotid artery, and severity of plaques in the aorta.6 The 
associations between CVD risk factors and PWV that we observed in this 
Table 5.  Components of variance for carotid-femoral PWV, carotid IMT, and 
plaque score
Proportion of variance 
associated with covariates
Heritability  
(SE, p value)
PWV* Model A 0.451 0.361 (0.087, < 0.001)
Model B 0.532 0.257 (0.084, < 0.001)
IMT* Model A 0.612 0.411 (0.073, < 0.001)
Model C 0.657 0.348 (0.078, < 0.001)
Plaque score Model A 0.402 0.279 (0.071, < 0.001)
Model D 0.435 0.205 (0.072, < 0.001)
Model A includes age and gender. 
Model B includes age, gender, mean arterial pressure, LDL cholesterol, fasting glucose, and heart 
rate. 
Model C includes age, gender, body mass index, systolic and diastolic blood pressures, LDL and 
HDL cholesterol, fasting glucose, smoking and heart rate. 
Model D includes age, gender, body mass index, systolic blood pressures, LDL and HDL 
cholesterol, and smoking. 
HDL: high density lipoprotein; IMT: intima media thickness; LDL: low density lipoprotein; 
PWV: pulse wave velocity; SE: standard error. 
* Natural logarithm transformation was performed to obtain a normal distribution of the residuals.
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isolate were in line with previous findings.25 In this study, we investigated 
to what extent genetic factors contribute to the variation of PWV in this 
population and if this is comparable to the contribution of genetic factors 
to the variance of atherosclerosis measurements; carotid IMT and plaque 
score. For PWV, we found a heritability of 0.36. This estimate is quite  
similar to the heritability of IMT in our study. After adjustment for  
appropriate cardiovascular risk factors, the PWV heritability was reduced 
to 0.26. Although this reduction in the heritability estimate is greater than 
that observed for other traits in our study, we also observed a greater  
increase in the proportion of variance associated with the covariates. Some 
of these covariates are genetically mediated themselves, such as blood  
pressure (presented in this analysis as MAP).
Duggirala et al 12 reported a considerably higher heritability of carotid 
artery IMT (h2 = 0.92) among a small sample (46 sibships of various sizes) 
from Mexico City; however, the authors suggested that their findings 
should be interpreted with caution because the characteristics of their data 
(small sample of sibships only) might have inflated their heritability estimate. 
In contrast, the findings from the present study are similar to those in 
previous reports, suggesting that genetic factors account for 0.30 to 0.40 of 
IMT variation in families, after adjustment for traditional CVD risk  
factors.14-17 
IMT is a standardised measurement of atherosclerosis with relatively 
high precision. This measurement, however, takes into account both intima 
and media thickness of the arterial wall, and, in early ages, it might be 
influenced by arterial hypertrophy rather than atherosclerosis. In this study, 
we also considered the genetic basis of another marker of subclinical  
atherosclerosis, the carotid plaque score. Compared with IMT, plaque score 
is considered to be a more accurate measurement of atherosclerosis,  
although it is less quantitative than IMT.26 The observed associations 
between CVD risk factors and plaque score in our study were comparable 
to previous findings.18,27 We found a heritability estimate of 0.28, which 
decreased to 0.21 after adjusting for the established cardiovascular risk  
factors. These heritability estimates were fairly similar to an earlier  
published study18 performed in the San Antonio Family Heart Study, also 
using a randomly ascertained study population.
It should be noted that direct comparison of the heritability estimates 
from the present study with those obtained from other studies is problematic. 
Different study designs, adjustments for covariates, and population specific 
environmental contributions to the phenotypic variance might result in  
different heritabilities even when the genetic variance estimates in the  
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different populations are similar. In the present study, we used a huge single 
pedigree, the largest pedigree used so far to study heritability estimates.  
Previously published studies were mainly based on sib-pair analyses or  
multiple families selected on the basis of disease status with relatively small 
sizes. In contrast, the members of our extended pedigree represent a random 
sample of our study population and were not ascertained through persons 
with a specific disease status. This allows us to make inferences about these 
heritabilities at the population level. At the same time, it is important to 
realise that the genetic contribution to a specific trait may not be constant 
between populations, even when they inherited the same genetic make-up. 
For instance, genes involved in salt sensitivity will not express in a population  
with low salt intake. Presence or absence of an environmental factor (diet, 
physical activity, life style, etc.) may indicate whether or not a certain  
genetic make-up plays an important role in the variability of a trait. 
The inclusion of covariates that are known to aggregate in families may 
have affected our results. Indeed, some of the covariates that we included 
are themselves genetically mediated, for example blood pressures and 
plasma lipid levels. Including such variables in the heritability calculations 
could reduce the heritability estimates whenever there are pleiotropic effects 
of genes on the covariates and the phenotypic measures under study. The 
heritability estimates derived from a model adjusted for age and gender 
indicate to what extent the genetic factors (directly or through other  
covariates) contribute to the variance of the trait under study. On the other 
hand, estimated heritabilities from a fully adjusted model represent only 
the contribution of the genes that are acting independently of the  
considered covariates. 
In summary, we report for the first time that a substantial proportion of 
the variability in PWV is explained by genetic factors. This heritability was 
quite similar to the heritability estimates of IMT and plaque score in our 
study. Our findings stimulate the search for genes responsible for arterial 
stiffness. 
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Chapter 3.1 
The ACE I/D polymorphism and 
carotid artery wall thickness: 
a meta-analysis
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Abstract 
 
Many studies have investigated the association between the angiotensin converting 
enzyme (ACE) gene insertion/deletion (I/D) polymorphism and carotid artery intima 
media thickness (IMT); however, most studies were small and conducted in selective 
samples. The aim of this sudy was to evaluate this association by performing a meta-
analysis on published articles.
We searched Medline for articles studying the association between the ACE I/D 
polymorphism and carotid IMT. Twenty-six studies were found from which 23 articles 
qualified to enter the meta-analysis containing 9833 subjects. We classified those 
articles on the bases of their samples into high-risk and low-risk populations and also 
Caucasian and Asian ethnic groups. IMT was used as a continuous variable, and data 
were analysed using the Cochrane Review Manager.
A significant positive association was present between the D allele and common 
carotid IMT (weighted mean difference between DD and II genotypes = 0.23 mm×10–1,  
p < 0.01). The association was stronger among high-risk populations. The point 
estimates of DD versus II were higher than those of ID versus II. 
Our meta-analysis showed evidence of a positive association between the D allele of 
the ACE gene and common carotid IMT. The overall results were concordant in both 
ethnic groups. 
35
ACE and Atherosclerosis
Introduction
 
The angiotensin converting enzyme (ACE), a key enzyme in the renin 
angiotensin system, plays an important role in vascular wall homeostasis.1-3 
Regulation of circulation and probably tissue ACE levels are under strong 
genetic control.4,5 The ACE gene located on chromosome 17q23 has an 
insertion/deletion (I/D) polymorphism in the non-coding region of the 
gene. The insertion that gives rise to the I allele is an alu repeat (287 bp)4 
in intron 16 of the ACE gene, while the D allele results from the absence 
of the above insertion. It has been shown that a higher plasma ACE level is 
present in subjects with the D compared with the I allele.4,5
Numerous studies have reported a relation between the D allele and 
cardiovascular diseases6-9 but findings have been controversial.10-13  
Aditionally, results from a large number of studies on the association between 
the ACE polymorphism and carotid artery intima media thickness (IMT), 
which was used as a measure of atherosclerosis, have been controversial. 
Some studies found a positive association between the D allele and IMT,14-20  
whereas others failed to find such a relation.21-39 However, the studies were 
conducted in selective and heterogeneous groups from low-risk populations 
to hypertensive or diabetic patients. Furthermore, the sample sizes of these 
studies have been relatively small. The aim of our study was to evaluate the 
effect of this polymorphism on carotid IMT by performing a meta-analysis 
using all studies published until October 2002.
 
Materials and methods
Identification of studies 
We searched Medline for all publications relating to association studies  
using the ACE I/D polymorphism and carotid IMT. References from 
retrieved publications were checked for any additional studies. Twenty-six 
articles were identified.14-39 Two studies that used familybased design, were 
excluded.24,31 One study did not report detailed statistics for IMT  
measurement,37 and therefore was not included in the meta-analysis.  
Furthermore, two case-control studies did not report detailed results of 
their controls groups,19,39 and only case groups were included.
In total, 23 articles were entered into the meta-analysis, from which 17 
studies have been conducted in Caucasian populations. Most of the sample 
sizes were composed of less than 500 subjects. Three studies used the case-
control design,18,19,39 and six other studies included only individuals at high 
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risk of atherosclerosis.15,20,23,28,32,38 In total, there were 1448 patients with 
hypertension, type 1 diabetes, type 2 diabetes, cerebrovascular or arterial 
occlusive diseases. Other studies used either a random sample of the general 
population or relatively healthy subjects. 
Four studies used samples that included only men.16,27-29 Among other 
studies that used both genders, three studies performed comparisons  
between men and women in regard to an association between the  
polymorphism and carotid IMT.26,33,35 None of them found any evidence 
that the association may be different between two genders. Therefore, both 
genders were included in the meta-analysis.
Measurements of carotid artery IMT were done in all the studies by 
means of B-mode ultrasound examinations. Participants were examined in 
a supine position with slight extension of the neck, and measurements of 
the IMT were performed using a 5 to 10 MHz transducer along the  
segment 10 to 30 mm proximal to the origin of the carotid bulb. Some 
studies measured IMT in several arterial sites, and various cut points were 
used to convert the IMT from a continuous variable to a nominal variable. 
Therefore, in order to make the studies more comparable, we used IMT 
measurement of the far wall of the common carotid artery as a continuous 
variable whenever several statistics were presented in original articles. 
In most of the studies the genotype frequencies were consistent with 
Hardy-Weinberg equilibrium (HWE). Deviations from HWE were found 
in some studies among high-risk populations. Because deviation may  
occur in diseased populations if there is an association between disease and 
the allele, which may have been the case in the present studies, we did not 
exclude them from the meta-analysis.
Statistical analyses 
We entered the available data in the Cochrane Review Manager (RevMan 
version 4.1.1) and analysed them with Metaview 4.1. The method of moments  
proposed by DerSimonian and Laird40 has been used to calculate the weighted  
mean differences (WMDs) in a random effects model for the pooled data. 
We used the funnel plot to examine publication bias of reported associations. 
In addition to the total group, we analysed the studies using the high-
risk populations separately from low-risk/general populations, since it has 
been shown that the association with the gene could be different because of 
risk factor profiles.14,18,19 Furthermore, we classified the articles into  
studies of Asians and Caucasians because genotype frequencies as well as 
the prevalence of cardiovascular diseases are reported to be different among 
37
ACE and Atherosclerosis
ethnic groups.12,13 The effect of the ACE gene variant was assessed by use of  
comparisons between DD and II, DD and ID, and ID and II genotype groups.
Whenever the standard error was reported in the original article, the  
value of the standard deviation has been calculated, and all descriptive data 
are expressed as mean ± standard deviation. The mean differences are  
presented in mm×10–1 with the 95% confidence interval for each difference. 
The p values are presented with two decimal places.
 
Results
 
In total, the studies contained 9833 subjects. Details of the individual 
studies are shown in Table 1. Mannami et al 35 from Japan and Hung et al 30 
from Australia used the largest sample sizes. Almost all studies used middle-
aged samples of the population. 
The total frequency of the D allele was 46.2%. There was a high range 
for the DD genotype frequencies: from 13.0% in Mannami et al 35 to 
43.1% in Nergizoglu et al.19 Table 2 shows the allele frequencies and  
distribution of genotypes in the individual studies. The lowest frequencies 
for the DD genotype have been observed in Asian populations. 
The carotid IMTs in different studies according to the three ACE  
genotype groups are presented in Table 3. There was only one study that 
reported a positive effect of the I allele on carotid IMT.39 This study  
introduced a highly significant heterogeneity (p = 0.002) and was excluded 
from the rest of the analyses. 
Overall, there was a significant positive association between the D allele 
and carotid IMT (WMD = 0.23 mm×10–1 between DD and II, p < 0.01) 
(Table 4). Among high-risk populations, this weighted mean difference 
was significant in both Caucasians (WMD = 0.49 mm×10–1, p < 0.01) and 
Asians (WMD = 1.74 mm×10–1, p < 0.01). In low-risk/general populations, 
however, the association was positively significant only among Caucasians 
(WMD = 0.14 mm×10–1, p = 0.02). Table 4 shows the weighted mean 
differences of carotid IMT and corresponding 95% confidence intervals 
between the genotypes. The point estimates of the difference between DD 
and II were generally higher than the point estimates of ID versus II. The 
mean differences between DD and II in the individual studies and the 
weighted pooled data are shown in Figure 1.
Figure 2 presents the funnel plot for two different ethnic subgroups. The 
plot for Caucasians is quite symmetric, but this is not the case for Asians, 
suggesting a publication bias in these populations.
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Table 1.  Characteristics of the association studies between the ACE I/D 
  polymorphism and carotid IMT
Study Year Country Sample size, n Age (years)*
Low-risk/general populations†
Arnett et al 25 1998 United States 495 59.0 ± 6.1
Balkestein et al 21 2002 Belgium 380 39.8 ± 15.7
Castellano et al 14 1995 Italy 187 57.8 ± 3.4
Dessì-Fulgheri et al 22 1995 Italy 240 53.4 ± 7.0
Ferrières et al 27 1999 France 355 53.7 ± 7.0
Girerd et al 26 1998 France 340 49.0 ± 12.0
Huang et al 29 1999 Finland 219 54.1 ± 2.9
Hung et al 30 1999 Australia 1106 53.3 ± 12.5
Kauma et al 17 1996 Finland 515 51.4 ± 6.0 
Pujia et al 16 1996 Italy 132 50.4 ± 10.3
Sass et al 33 1998 France 150 41.2 ± 4.2
Kogawa et al 18 (controls) 1997 Japan 235 50.9 ± 10.6
Mannami et al 35 2001 Japan 3657 59.7 ± 11.8
Tabara et al 34 2001 Japan 205 70.0 ± 9.0
Watanabe et al 36 1997 Japan 169 59.2 ± 10.4
High-risk populations‡
Diamantopoulos et al 38 2002 Greece 184 61.4 ± 7.7
Frost et al 23 1998 Germany 148 30.1 ± 6.6
Markus et al 39 (cases) 1995 United Kingdom 101 64.8 ± 9.0
Nergizoglu et al 19 (cases) 1999 Turkey 51 36.2 ± 9.3
Pit’ha et al 28 1999 Czech Republic 47 61.9 ± 2.5
Taute et al 32 2000 Germany 98 60.5 ± 8.9
Hosoi et al 15 1996 Japan 288 59.5 ± 10.6
Jeng20 2000 China 175 56.8 ± 10.3
Kogawa et al 18 (cases) 1997 Japan 356 59.6 ± 10.6
ACE: angiotensin converting enzyme gene; I/D; insertion/deletion; IMT: intima media thickness.
* Age is presented as mean ± standard deviation. 
† Low-risk populations included subjects without chronic medication, non-smokers, low-risk 
outpatients, healthy subjects and controls (definition was given in original articles). 
‡ High-risk populations included symptomatic cerebrovascular disease, type 1 and 2 diabetes, 
non diabetic haemodialysis, and hypertensive patients. 
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Table 2.  Distribution of genotype and allele frequencies in individual studies
Frequency 
of the D 
allele (%)*
Genotype frequency, n (%)
Study II ID DD p (HWE)
Low-risk/general populations
Arnett et al 25 56.4 88 (17.8) 256 (51.7) 151 (30.5) 0.25
Balkestein et al 21 45.8 116 (30.5) 180 (47.4) 84 (22.1) 0.37
Castellano et al 14 64.2 23 (12.3) 88 (47.1) 76 (40.6) 0.75
Dessì-Fulgheri et al 22 64.6 23 (9.6) 124 (51.7) 93 (38.8) 0.05
Ferrières et al 27 59.2 70 (19.7) 150 (42.3) 135 (38.0) 0.02
Girerd et al 26 59.0 57 (16.8) 165 (48.5) 118 (34.7) 0.96
Huang et al 29 58.0 42 (19.2) 100 (45.7) 77 (35.2) 0.35
Hung et al 30 55.2 228 (20.6) 535 (48.4) 343 (31.0) 0.46
Kauma et al 17 54.4 103 (20.0) 264 (51.3) 148 (28.7) 0.45
Pujia et al 16 61.4 16 (12.1) 70 (53.0) 46 (34.8) 0.17
Sass et al 33 51.3 33 (22.0) 80 (53.3) 37 (24.7) 0.41
Kogawa et al 18 (controls) 38.3 87 (37.0) 116 (49.4) 32 (13.6) 0.50
Mannami et al 35 35.5 1540 (42.1) 1640 (44.8) 477 (13.0) 0.22
Tabara et al 34 36.3 83 (40.5) 95 (46.3) 27 (13.2) 0.98
Watanabe et al 36 40.8 62 (36.7) 76 (45.0) 31 (18.3) 0.37
High-risk populations
Diamantopoulos et al 38 60.9 29 (15.8) 86 (46.7) 69 (37.5) 0.80
Frost et al 23 60.5 31 (20.9) 55 (37.2) 62 (41.9) 0.01
Markus et al 39 (cases) 58.9 18 (17.8) 47 (46.5) 36 (35.6) 0.70
Nergizoglu et al 19 (cases) 64.7 7 (13.7) 22 (43.1) 22 (43.1) 0.69
Pit’ha et al 28 56.4 8 (17.0) 25 (53.2) 14 (29.8) 0.58
Taute et al 32 57.1 19 (19.4) 46 (46.9) 33 (33.7) 0.68
Hosoi et al 15 37.2 124 (43.1) 114 (39.6) 50 (17.4) 0.01
Jeng20 43.1 65 (37.1) 69 (39.4) 41 (23.4) 0.01
Kogawa et al 18 (cases) 37.8 147 (41.3) 149 (41.9) 60 (16.9) 0.04
HWE: Hardy-Weinberg equilibrium. 
* Allele frequencies are recalculated using the genotype frequencies. 
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Table 3.  Comparison of IMT in the three genotype groups in individual studies
Genotype group
Study II ID DD p value*
Low-risk/general populations
Arnett et al 25 7.2 ± 1.5 7.3 ± 1.6 7.3 ± 1.5 NS
Balkestein et al 21 5.6 ± 1.6 5.9 ± 2.3 5.8 ± 1.7 NS
Castellano et al 14 7.5 ± 1.9 6.8 ± 1.9 7.4 ± 1.7 0.06
Dessì-Fulgheri et al 22 10.2 ± 2.0 10.6 ± 3.0 10.5 ± 4.0 NS
Ferrières et al 27 6.3 ± 1.2 6.2 ± 1.0 6.4 ± 1.2 NS
Girerd et al 26 5.4 ± 1.0 5.4 ± 1.3 5.5 ± 1.1 NS
Huang et al 29 10.4 ± 2.3 10.8 ± 3.3 10.1 ± 1.9 NS
Hung et al 30 7.1 ± 1.4 7.1 ± 1.4 7.1 ± 1.5 NS
Kauma et al 17 8.1 ± 1.8 8.0 ± 1.5 8.3 ± 1.9 NS
Pujia et al 16 7.0 ± 0.8 7.6 ± 0.8 7.8 ± 0.7 0.02
Sass et al 33 5.2 ± 0.4 5.4 ± 0.6 5.3 ± 0.4 NS
Kogawa et al 18 (controls) 6.3 ± 1.6 6.3 ± 1.7 6.4 ± 1.7 NS
Mannami et al 35 8.7 ± 1.4 8.7 ± 1.4 8.7 ± 1.2 NS
Tabara et al 34 7.9 ± 1.2 8.0 ± 1.4 8.1 ± 1.4 NS
Watanabe et al 36 10.2 ± 3.1 11.0 ± 3.1 11.0 ± 3.1 NS
High-risk populations
Diamantopoulos et al 38 9.4 ± 2.0 9.7 ± 2.0 9.8 ± 2.1 NS
Frost et al 23 6.2 ± 1.5 6.3 ± 1.8 6.3 ± 1.3 NS
Markus et al 39 (cases) 11.4 ± 4.0 9.4 ± 2.8 8.1 ± 2.8 < 0.05†
Nergizoglu et al 19 (cases) 7.1 ± 0.5 7.6 ± 0.9 8.0 ± 1.0 < 0.05
Pit’ha et al 28 7.2 ± 1.3 7.1 ± 1.2 7.5 ± 1.6 < 0.10
Taute et al 32 10.1 ± 2.9 11.0 ± 2.5 10.6 ± 2.6 NS
Hosoi et al 15 10.0 ± 4.1 11.1 ± 6.1 12.0 ± 6.2 0.04
Jeng20 7.4 ± 2.7 7.6 ± 3.1 8.8 ± 3.5 0.06
Kogawa et al 18 (cases) 9.9 ± 3.6 10.6 ± 5.4 12.0 ± 5.9 < 0.05
NS indicates not significant at p = 0.10 level. IMTs are presented as mean ± standard deviation 
(mm×10–1). 
IMT: intima media thickness.
* p values as reported in the original articles, rounded to two decimal places. 
† Association with the I allele is present. 
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Table 4.   Weighted mean difference of carotid IMT between genotype groups 
WMD (95% CI), mm×10–1
Study group DD versus II DD versus ID ID versus II
Low-risk/general populations
Caucasians 0.14 (0.02, 0.26) 0.08 (–0.03, 0.19) 0.09 (–0.04, 0.21)
Asians –0.02 (–0.14, 0.11) –0.06 (–0.18, 0.07) 0.04 (–0.05, 0.13)
Total 0.10 (0.00, 0.20) 0.04 (–0.05, 0.12) 0.07 (–0.01, 0.16)
High-risk populations
Caucasians* 0.49 (0.14, 0.84) 0.15 (–0.16, 0.46) 0.32 (–0.02, 0.67)
Asians 1.74 (0.87, 2.62) 1.20 (0.27, 2.12) 0.59 (–0.05, 1.22)
Total 0.74 (0.28, 1.19) 0.26 (–0.04, 0.55) 0.38 (0.08, 0.69)
Overall 0.23 (0.08, 0.37) 0.08 (–0.02, 0.17) 0.09 (0.01, 0.17)
CI: confidence interval; IMT: intima media thickness; WMD: weighted mean difference. 
* Excluding the study of Markus et al.39
Discussion
 
In this study, we pooled the data of more than 9800 subjects from available 
published studies to compute an estimate of the association between the 
insertion/deletion polymorphism of the ACE gene locus and the common 
carotid intima media thickness. We calculated the weighted mean difference 
between every two genotypes and presented the differences among  
Caucasians and Asians in low-risk and high-risk groups separately. The 
significant weighted mean differences between DD and II among both 
low-risk and high-risk populations support the positive association between 
the D allele and carotid IMT. Although we could not show the difference 
between DD and ID, the point estimates for the mean differences between 
DD and II were generally higher than those of the difference between ID 
and II, suggesting an allele-dose effect of the allele. 
In a few studies the genotype frequencies were not consistent with 
HWE. Almost all those studies used high-risk populations, and deviation 
from HWE is expected among such populations. Laboratory error is not 
very likely because genotyping has been performed using standard protocols 
in all the studies and overdetection of the D allele has been corrected by 
performing a second polymerase chain reaction. The most likely explanation 
is a higher selection of the DD genotype because of the background diseased 
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Figure 1.  Weighted mean difference and 95% confidence intervals of the carotid 
IMT between DD and II genotypes in low-risk (top) and high-risk 
(bottom) populations
Study WMD (random) 95% CI Weight % WMD (random) 95% CI
Caucasians    
Arnett et al 25  5.64 0.11 (–0.29, 0.51)
Balkestein et al 21  4.26 0.26 (–0.21, 0.73)
Castellano et al 14  1.30 –0.10 (–0.98, 0.78)
Dessì-Fulgheri et al 22  0.76 0.30 (–0.85, 1.45)
Ferrières et al 27  7.19 0.10 (–0.25, 0.45)
Girerd et al 26  7.64 0.11 (–0.22, 0.44)
Huang et al 29  1.50 –0.30 (–1.11, 0.51)
Hung et al 30  12.68 0.00 (–0.24, 0.24)
Kauma et al 17  4.33 0.20 (–0.26, 0.66)
Pujia et al 16  4.77 0.78 (0.34, 1.22)
Sass et al 33  18.85 0.11 (–0.07, 0.29)
Subtotal (95% CI)  68.91 0.14 (0.02, 0.26)
Test for heterogeneity: chi-square = 11.46, df = 10 (p = 0.32)
Test for overall effect: z = 2.26 (p = 0.02)   
Asians    
Kogawa et al 18 (controls)  2.06 0.11 (–0.58, 0.80)
Mannami et al 35  25.68 –0.04 (–0.17, 0.09)
Tabara et al 34  2.79 0.20 (–0.39, 0.79)
Watanabe et al 36  0.56 0.80 (–0.54, 2.14)
Subtotal (95% CI)  31.09 –0.02 (–0.14, 0.11)
Test for heterogeneity: chi-square = 2.19, df = 3 (p = 0.53)
Test for overall effect: z = 0.26 (p = 0.79) 
Total (95% CI)  100.00 0.10 (0.00, 0.20)
Test for heterogeneity: chi-square = 16.78, df = 14 (p = 0.27) 
Test for overall effect: z = 1.90 (p = 0.06) 
Caucasians    
Diamantopoulos et al 38  15.61 0.40 (–0.48, 1.28)
Frost et al 23  22.12 0.10 (–0.52, 0.72)
Nergizoglu et al 19 (cases)  23.95 0.90 (0.34, 1.46)
Pit’ha et al 28  10.04 0.24 (–0.99, 1.47)
Taute et al 32  6.83 0.50 (–1.08, 2.08)
Subtotal (95% CI)  78.56 0.49 (0.14, 0.84)
Test for heterogeneity: chi-square = 3.79, df = 4 (p = 0.43) 
Test for overall effect: z = 2.76 (p < 0.01) 
Asians    
Hosoi et al 15  5.16 2.00 (0.14, 3.86)
Jeng20  9.58 1.40 (0.13, 2.67)
Kogawa et al 18 (cases)  6.70 2.10 (0.50, 3.70)
Subtotal (95% CI)  21.44 1.74 (0.87, 2.62)
Test for heterogeneity: chi-square = 0.55, df = 2 (p = 0.76)  
Test for overall effect: z = 3.90 (p < 0.01) 
Total (95% CI)  100.00 0.74 (0.28, 1.19)
Test for heterogeneity: chi-square = 11.09, df = 7 (p = 0.13) 
Test for overall effect: z = 3.17 (p < 0.01) 
IMT mean difference (DD versus II) (mm×10–1)
CI: confidence interval; IMT: intima media thickness; WMD: weighted mean difference.
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populations. There was still one study among low-risk populations that 
did not follow the HWE.27 However, we considered excluding these studies 
from our meta-analysis and the results did not materially change.
Most of the studies used similar transducers (7.5 MHz) to measure IMT 
at the same segment of the common carotid artery (10 mm proximal to 
the carotid bulb). On the other hand, any possible measurement error will 
be presented equally in all three genotypes and because we used weighted 
mean differences in our analyses, it is not likely to induce an error in our 
results. The study by Sass et al 33 had the smallest standard deviation of 
IMT measurements and consequently gained a relatively large weight in 
the meta-analysis, whereas it comprised only 2% of the total sample size. 
Excluding this study did not materially change the results, ruling out the 
possibility of overweighting effect of this study on final findings.
It is important to mention that there is a large variability of case  
selection among the high-risk group. However, the fact that all of those 
study populations are at high risk of atherosclerosis means that they share 
some genetic-environmental backgrounds that make them susceptible for 
the disorder; in this sense, they may be considered homogenous. Possible 
explanations for the greater gene effect observed in this group could be the 
interaction between those background factors and the ACE gene as well as 
the greater variation in IMT among them. 
An important source of bias in every meta-analysis is publication bias 
because the likelihood of publishing a study could be related to the results 
of that study. However, among our meta-analysis, there have been many 
studies published with negative findings.21-23,25-30,32-35 Although the funnel 
plot for Asians is not symmetric, the overall results of both ethnic groups 
are concordant, indicating that this bias cannot affect the final result. 
On the other hand, funnel plot asymmetry is not always caused by  
publication bias. True heterogeneity may also lead to funnel plot asymmetry. 
For example, significant difference may be seen only in high-risk  
individuals, and these high-risk people are usually more likely to be  
included in small studies. This is particularly true in our meta-analysis 
because all the significant associations in Asians have been observed among 
the studies from high-risk populations. Language bias or citation bias also 
could be an important source in this group of studies, meaning that the 
studies without significant findings are preferentially published in languages 
other than English and less likely to be cited in other articles. Finally, it is 
possible, of course, that an asymmetrical funnel plot arises simply by chance.
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Figure 2. Funnel plots (DD versus II) for Caucasians (top) and Asians (bottom)
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SE: standard error; WMD: weighted mean difference.
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In summary, we found evidence of a positive association between the  
presence of the D allele of the ACE gene with common carotid IMT in 
a meta-analysis of 23 published articles (9833 subjects) that was stronger 
among high-risk populations. 
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Chapter 3.2
The ACE I/D polymorphism and 
carotid artery wall thickness:
the Rotterdam Study
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Abstract
Studies on the role of the insertion/deletion (I/D) polymorphism of the gene coding 
for angiotensin converting enzyme (ACE) in atherosclerosis have been inconsistent. 
In a meta-analysis, we recently showed that this relationship is stronger in high-
risk populations. In this paper, we used a combined functional and population 
based approach to investigate the gene-environment interaction of the ACE I/D 
polymorphism in relation to carotid artery wall thickness. The study was part of the 
Rotterdam Study, a prospective population based cohort study. In 5321 subjects, IMT 
was measured in the carotid arteries by ultrasonography and the ACE genotypes were 
determined by size analysis of polymerase chain reaction products. 
In multiple regression analysis, I/D polymorphism and smoking were the main 
determinants for plasma ACE levels (r2 = 0.28). There was a positive association 
between the D allele of the I/D polymorphism and carotid artery wall thickness among 
current smokers (p = 0.03). Subjects carrying only one of the risk factors (smoking or 
the D allele) did not show significant differences in IMT compared with the  
non-/former smokers group carrying two I alleles, while carriers of both risk factors 
had significant higher IMT. The association was not present in non-/former smokers. 
The results provide further evidence that genetic and environmental factors interact 
in the formation of the arterial lesions. This study shows that large population based 
studies could be extremely helpful in unravelling the genetic origin of complex diseases 
such as atherosclerosis. 
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Introduction
Angiotensin converting enzyme (ACE) is a key component in the renin 
angiotensin system, converting angiotensin I to angiotensin II.1 It also 
inactivates vasodilator bradykinin. Both peptides play central roles in blood 
pressure regulation and are considered to be important in the pathogenesis 
of cardiovascular diseases. ACE levels in plasma and tissue are under genetic 
control.2-4 There is a common insertion/deletion (I/D) polymorphism in 
the ACE gene characterised by the presence or absence of a 287 bp alu  
repeat. Subjects with the DD genotype have higher plasma ACE levels 
compared with those with the ID and II genotypes.2,3 This finding predicts 
that carriers of this genotype may have increased blood pressure and a 
higher prevalence of cardiovascular diseases. 
Findings on the association between the ACE I/D polymorphism and 
atherosclerosis using ultrasonographic measurements of carotid arteries have 
been inconsistent. Some studies showed a relation of atherosclerosis with 
presence of the D allele,5-8 while others have failed to show such  
association.9,10 The majority of the studies conducted until now were based 
on relatively small sample sizes, which may in part explain the inconsistency, 
particularly when interactions were studied.11 A recent evaluation of  
candidate gene studies in a meta-analysis demonstrated that large studies are 
needed to show the effects of the genes involved in complex traits.11  
Recently, we performed a meta-analysis of the association between this poly-
morphism and carotid artery intima media thickness (IMT), using the studies 
conducted until October 2002.12 When pooling the data of 23 articles (9833 
subjects), we found that carriers of the DD genotype have an increased 
thickness of common carotid IMT. The correlation was most pronounced in 
high-risk populations, suggesting gene-environment interactions.12 
From our meta-analysis it is not clear which factor is interacting with 
the ACE gene. As studies of gene-environment interactions are prone to 
false positive and negative findings, we used a combined functional and 
population based approach. To unravel the role of interactions of the ACE 
I/D polymorphism with other factors, we aimed to identify the non-genetic 
determinants of the renin angiotensin system, specifically those associated 
with plasma ACE levels. We studied various vascular risk factors in  
relation to ACE levels and found that only smoking was a determinant of 
ACE levels in addition to the ACE gene. As a second step, we investigated 
the ACE gene and its interaction with smoking in relation to carotid  
ultrasonographic measurements and found evidence that smoking is a  
factor modifying the prevalence of ACE related carotid artery lesions. 
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Materials and methods
Study population
This study is part of the Rotterdam Study, an ongoing population based 
follow up study designed to investigate the determinants of chronic diseases 
in the elderly; it has been described in more detail elsewhere.13 In brief, 
baseline data were collected between March 1990 and July 1993 from 7983 
subjects, aged 55 years or older, living in Ommoord, a suburb of Rotterdam, 
The Netherlands.13 The study was approved by the Medical Ethics  
Committee of Erasmus University, and written informed consent was  
obtained from all participants.
All participants were interviewed at home by a trained research assistant 
using computerised questionnaires, and they subsequently visited the study 
centre. Smoking history was assessed during the interview at home and  
participants were categorised as never, former, or current smokers. At the 
study centre an extensive physical examination was performed on each  
participant, including ultrasonography of the carotid arteries. A blood  
sample was drawn, and serum and plasma were stored at –80 °C. 
Carotid ultrasonography
Carotid atherosclerosis was assessed by duplex scan ultrasonography of the 
carotid arteries, using a 7.5 MHz linear array transducer (ATL, Ultramark 
IV). Measurements of IMT were performed offline using the still images 
recorded on videotape. Details about this measurement have been published 
previously.14 Briefly, the interfaces of the far and near walls of the distal  
common carotid artery are marked over a length of 10 mm. We used the 
average of the measurements of three still images of both the left and right 
arteries. Carotid IMT was determined as the mean of the IMT of near and 
far wall measurements of both the left and right arteries. Results from a  
reproducibility study of IMT measurements have been published elsewhere.15 
The mean differences ± standard deviation in common carotid IMT between 
paired measurements of sonographers, readers, and visits were –0.004 ± 0.10 
mm, 0.066 ± 0.07 mm, and –0.013 ± 0.13 mm, respectively.
We defined plaques as focal widening of the vessel wall with protrusion 
into the lumen, composed of calcified or non-calcified components. The 
protrusion was evaluated by eye, without measuring the thickness of the  
lesions or of the adjacent structure. The total plaque score reflected the  
total number of sites with plaques and ranged from 0 to 6 (left and right 
side common carotid arteries, bifurcation, and internal carotid arteries).
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Laboratory assessments 
Colorimetric determination of ACE activity levels was performed in the 
stored plasma samples (–80 °C). Because of cost considerations, ACE levels 
were assessed in a random group of 215 individuals. The measurements 
were carried out with a kit by Fujirebio Inc, which uses a p-hydroxy-Hip-
His-Leu substrate.16 Fluorimetric assay of ACE activity levels in plasma was  
performed by measuring the release of His-Leu from the substrates Hip-
His-Leu and Z-Phe-His-Leu.17,18
DNA was isolated from blood samples using a standard procedure (the 
salting out method).19 The II, ID, and DD genotypes were detected using 
the polymerase chain reaction (PCR) technique according to the method 
of Lindpaintner et al 20 with some modifications. The insertion and dele-
tion alleles of the ACE gene were identified using a set of oligonucleotide 
primers flanking the polymorphic site in intron 16. The final volume of the 
PCR mix was 20 µl containing 50 ng DNA as template and 1×PCR buffer 
(Gibco), 1.3 mmol/L MgCl
2
, 200 µmol/L dNTPs, 20 pmol primer mix, 
and 0.35 U Taq polymerase in a PE9600 PCR machine. The thermocycling 
procedure was completely identical to the method of Lindpaintner et al.20 
The result of amplification was a 319 bp and a 597 bp amplicon for the D 
and the I alleles, respectively.
Because the D allele in heterozygous samples is preferentially amplified, 
there is a tendency towards misclassification of about 4 to 5 percent of ID 
genotype to DD. In order to avoid this, a second independent PCR was 
performed with a primer pair that recognises an insertion specific sequence. 
To optimise the second PCR, 10% DMSO, 0.35 U AmpliTaq Gold DNA 
polymerase and 1×GeneAmp PCR Gold buffer (Applied Biosystems) was 
added to the PCR mix with annealing temperature of 67 °C. The reaction 
yielded a 335 bp amplicon only if the I allele was present. All reactions 
were performed in 96 well plates and handled by a robot (Beckman  
Biomek® 2000).
In the post-PCR analyses, 10 µl of PCR product was loaded onto a 3% 
agarose gel. Fragments were visualised using etidium brominde staining and 
UV transillumination. Two independent investigators interpreted the pictures 
from each gel and all ambiguous samples were analysed a second time.
Statistical analyses
Hardy-Weinberg equilibrium was tested with the chi-square test. We 
analysed the distribution of conventional cardiovascular risk factors among 
three genotype groups by chi-square test for dichotomous variables and 
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by one way analysis of variance for continuous variables. Multiple linear 
regression analysis was used to analyse the relation between vascular risk 
factors and ACE levels. The differences in ACE levels and IMT between the 
smoking and genotype groups were tested using the general linear model 
univariate procedure, adjusted for age and gender. In addition, subjects  
were divided into two groups based on the number of plaques in the carotid 
arteries (0-2 plaques and 3 or more plaques). Logistic regression was used 
to estimate the adjusted odds ratios for the different genotype groups using 
subjects with the II genotype as reference. No adjustments were initially 
made for vascular risk factors such as hypertension, as they may act as  
intermediate factors. Interaction of the ACE genotype with smoking was 
tested using a multiplicative model. All statistical analyses were conducted 
using SPSS 11.0 for Windows.
Results
We performed our analyses on 5321 subjects for whom the complete data 
for ACE genotypes, IMT measurements, and smoking status were available. 
Data for at least one of the variables were missing in the remaining subjects 
due to logistic reasons; mainly because the subjects were too old or disabled 
to visit the research centre for the examination. In our sample, the frequency 
of the D allele was 53.3% and the distribution of the genotype and allele 
frequencies were in Hardy-Weinberg equilibrium (II, 21.7%; ID, 49.9%; 
and DD, 28.3%; p = 0.82). Among the remaining subjects for whom the 
genotype frequencies were available (n = 1548), no deviation from Hardy-
Weinberg equilibrium was observed. Furthermore, there was no significant 
difference in the genotype frequencies between the two samples (p = 0.44). 
Table 1 shows the demographic characteristics of the participants by the 
ACE genotypes. No significant differences were found among the three  
genotypes with respect to classical cardiovascular risk factors. The carriers 
of the D allele were significantly older than the II carriers but the difference 
was only 1.22 years. Furthermore, carriers of the DD genotype had a  
significantly higher mean systolic blood pressure and a higher mean of  
carotid IMT compared with the II genotype. Although there was a slight 
increase in the percentage of subjects with three or more plaques, the  
frequency did not increase significantly in carriers of the D allele compared 
with the II genotype (Table 1).
In the sample of 212 individuals for whom both plasma ACE levels and 
I/D genotypes were measured, the allele and genotype proportions were 
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Table 1.  Demographic characteristics of subjects according to the  
ACE I/D genotypes
ACE genotype
II (n = 1156) ID (n = 2657) DD (n = 1508)
Age (years) 68.03 ± 8.53 69.08 ± 8.67* 69.25 ± 8.89*
Male gender (%) 41.70 40.80 39.66
Body mass index (kg/m2) 26.39 ± 3.82 26.22 ± 3.65 26.31 ± 3.63
Current smoking (%) 22.88 23.60 20.82
Total cholesterol (mmol/L) 6.62 ± 1.28 6.66 ± 1.17 6.61 ± 1.21
HDL cholesterol (mmol/L) 1.34 ± 0.35 1.35 ± 0.35 1.35 ± 0.37
Systolic BP (mmHg) 137.67 ± 21.61 139.09 ± 22.66 140.01 ± 22.84*
Diastolic BP (mmHg) 73.48 ± 11.64 73.53 ± 11.63 73.73 ± 11.29
Hypertension (%)† 31.78 36.03* 35.05
Common carotid IMT (mm×10–1) 7.88 ± 1.53 7.99 ± 1.59 8.03 ± 1.59*
Number of carotid plaques ≥ 3 (%) 20.90 23.58 23.75
Continuous values are mean ± standard deviation. 
ACE: angiotensin converting enzyme gene; BP: blood pressure; HDL: high density lipoprotein; 
I/D: insertion/deletion; IMT: intima media thickness. 
* p < 0.05 compared with II genotype.
† Hypertension, defined as systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg or medication use. 
Table 2. Vascular risk factors and their association with plasma ACE levels
Variable Beta SE p value
ACE I/D polymorphism* 2.71 0.35 < 0.01
Current smoking 1.92 0.61 < 0.01
Age (years) –0.07 0.06 0.20
Male gender 0.63 0.54 0.24
Body mass index (kg/m2) 0.07 0.08 0.37
Total cholesterol (mmol/L) –0.19 0.23 0.42
HDL cholesterol (mmol/L) 0.95 0.76 0.22
Systolic BP (mmHg) –0.01 0.02 0.84
Diastolic BP (mmHg) –0.02 0.04 0.56
ACE (ACE): angiotensin converting enzyme (gene); Beta: regression coefficient; 
BP: blood pressure; HDL: high density lipoprotein; I/D: insertion/deletion; 
SE: standard error of the coefficient. 
* Number of the D alleles was used in the equation (II = 0, ID = 1, and DD = 2). 
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consistent with Hardy-Weinberg equilibrium (p = 0.48). In multiple linear 
regression analysis, the ACE I/D polymorphism and smoking were the only 
determinants of plasma ACE levels (Table 2). These two factors together 
explained 28% of the variation in enzyme levels in plasma (r = 0.53, p < 0.01). 
The levels of ACE were not significantly different between former smokers 
and non-smokers (14.83 ± 3.57 and 15.58 ± 3.87 U/L, respectively)  
therefore we combined these two groups. Overall, the ACE level was 1.8 
U/L higher in current smokers compared with non-/former smokers  
(p < 0.01). Although the difference in ACE levels between smokers and 
non-/former smokers was largest in the ID and DD group, it was not  
significantly different from the difference in the II group (Figure 1). 
When studying the joint effect of smoking and the ACE gene on IMT, 
there was a significant increase in mean carotid IMT in those carrying the 
D allele in current smokers (p value for trend was 0.04). The IMT  
difference (mean ± standard error) between DD and II genotypes in  
smokers was 0.26 ± 0.12 mm×10–1, (p = 0.03). In contrast, IMT was not 
significantly associated with the D allele among non-/former smokers  
(Figure 2). The p value for interaction between the ACE genotype and 
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Figure 1. Plasma ACE levels in different genotypes stratified by smoking status
Data are adjusted for age and gender. 
ACE: angiotensin converting enzyme. 
* Significantly different from the genotype II non-/former smokers group. 
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smoking status was 0.08. The differences between genotype groups in 
smokers reduced but did not disappear when adjusted for systolic blood 
pressure. Subjects carrying only one of the risk factors (smoking or the 
D allele) did not show significant differences in IMT compared with the 
genotype II non-/former smokers group, while carriers of both risk factors 
had significantly higher IMT (p < 0.01). 
The odds ratios of having three or more plaques in carotid arteries in 
current smokers were 1.14 (95% confidence interval (CI): 0.81, 1.59) and 
1.40 (95% CI: 0.96, 2.04) for ID and DD genotypes, respectively. This 
increase of odds ratios with the number of the D alleles was borderline  
significant (p = 0.07) while in non-/former smokers the odds ratios  
remained the same among genotype groups. 
Stratified analyses concerning the combined effect of the ACE  
polymorphism and other cardiovascular risk factors (hypertension,  
hyperlipidaemia, diabetes, obesity, age and gender) on carotid IMT did not 
show any significant differences among and between the stratified groups. 
In all the analyses the mean IMT difference between DD and II genotypes 
was less than 0.20 mm×10–1 and did not reach significance level (p > 0.10).
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Figure 2. Carotid IMT in different genotypes stratified by smoking status
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Data are adjusted for age and gender. 
IMT: intima media thickness.
* Significantly different from the genotype II non-/former smokers group. 
† Significantly different from the genotype II smokers group. 
58
C
h
ap
te
r 
3.
2 
 A
C
E
 a
nd
 I
M
T
: t
he
 R
ot
te
rd
am
 S
tu
dy
Discussion
In this study, we found a modest but significant association between the 
ACE I/D polymorphism and carotid IMT in the presence of smoking. In 
non-/former smokers, no significant association between the ACE genotype 
and IMT was observed.
This study is the largest population based study performed on the ACE 
I/D polymorphism and carotid artery lesions. The next largest study, which 
used a sample size of 3657 individuals in Japan21 failed to find a relation 
between the ACE and IMT. Difference in ethnicity could be a possible 
explanation; however, the problem in comparing findings is that the  
interaction between the ACE polymorphism and smoking was not studied 
by Mannami et al.21 Findings of other studies on the interaction between 
the ACE gene and smoking have not been consistent. An interaction  
between smoking and the ACE I/D genotype on atherosclerosis was  
reported in 1997 by Hibi et al,22 who showed a smoking associated effect 
of the ACE genotype on the severity of coronary atherosclerosis.22 Another 
study23 found an association between the ACE I/D and carotid IMT only 
among non-/former smokers, particularly those on chronic cardiovascular 
medication. Yet others failed to find evidence for such an interaction.24
Genetic studies aiming to uncover gene interactions are extremely prone 
to false positive and negative findings. To obtain internal consistency in our 
study, we studied not only the relation of the ACE gene to atherosclerosis 
but also to ACE levels, which have been studied extensively with regard to 
polymorphisms in the ACE gene.25-28 Since Rigat et al 2 reported in 1990 
that the ACE I/D polymorphism determines the plasma levels of the  
enzyme, many studies have replicated this finding.3,8,10 Our data also  
confirm that the presence of the deletion allele is significantly associated 
with the plasma ACE levels. The ACE levels in our study were in the same 
range as those from other population studies, which used the same method 
of measurement.8,29 Although ACE levels were determined in stored sera 
and laboratory drift may have occurred, such drift is unlikely to be  
associated with the ACE genotype. 
To unravel the role of interactions of the ACE I/D polymorphism with 
other vascular risk factors, we focused on identifying the determinants 
in the renin angiotensin system, specifically those associated with plasma 
ACE levels. In our population based study, we found that smoking is the 
only other factor related to plasma ACE levels, suggesting that they use the 
same pathways. The vascular risk factors that might be related to plasma 
ACE levels are not well known. In one report smoking and blood pressure30 
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and in another, male gender and history of hypertension31 correlated with 
the plasma ACE levels. In our sample, the I/D polymorphism and smoking 
together explained 28% of the variance in ACE levels. On average, current 
smokers had 1.8 U/L higher ACE level in plasma. Although the differences 
were not significant, in those carrying the ID and DD genotypes the effect 
of smoking on ACE levels was larger than in the II genotype. A possible  
effect of smoking on cleavage secretion of ACE from the endothelial cells 
may explain this finding.32 Additionally, there are indications that nicotine 
increases expression of a number of genes in the endothelium including ACE.33 
The values for IMT in our study strongly concurred with those reported 
by Tabara et al, 34 using a sample with the same age. In order to test if the  
observed association between the I/D polymorphism and carotid IMT in the 
presence of smoking was through blood pressure, we adjusted our analysis 
for systolic blood pressure. Our result suggests that blood pressure does not 
fully explain the association. Recently, it has been shown that the DD  
genotype is associated with a significant blunting in vasodilation through 
nitric oxide (NO) pathways (due to increased angiotensin II induced NO 
breakdown and/or reduced bradykinin mediated NO release).35 This finding 
is followed by other studies showing that smoking decreases plasma NO 
level36 that may lead to impaired endothelium dependent vasodilation.37,38 
In addition, NO has important antioxidative capacities, and smoking  
induces oxidative stress by reducing concentrations of NO and other 
antioxidants in plasma.39 Concurrently, carriers of the DD genotype show 
a lower antioxidant response compared with the II and ID genotypes.40 The 
above observations suggest that carriers of the DD genotype who smoke are 
likely to be at higher risk of atherosclerosis. 
Using a combined functional and population based approach provides us 
with an a priori hypothesis for the environmental factor(s) that may interact 
with the gene. However, the question remains if other environmental factors 
show the same pattern of interaction. The results of the stratified analyses 
showed no significant evidence for joint effect of the ACE polymorphism and 
other factors, prompting smoking as the best candidate for this interaction.
In summary, we found a positive association between the D allele of the 
I/D polymorphism and carotid IMT in the presence of smoking. This  
association provides further evidence that genetic and environmental factors 
interact in the formation of the arterial lesions. There may be various  
pathways underlying the observation of an effect of the ACE gene on IMT 
in smokers only, but on the basis of the present results it is not possible to 
fully explain the underlying mechanism. Our findings remain to be  
confirmed in future studies. 
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Chapter 3.3
The ACE I/D polymorphism and 
arterial stiffness: 
the Rotterdam Study
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Abstract
The insertion/deletion (I/D) polymorphism of the angiotensin converting enzyme 
(ACE) gene may be involved in structural arterial changes. The aim of the present 
study was to assess the relationship between the ACE I/D polymorphism and arterial 
stiffness among older adults.
The study was conducted within the Rotterdam Study, a population based cohort 
study including subjects aged 55 years or older. The II, ID, and DD genotypes of the 
ACE gene were determined by size analysis of polymerase chain reaction products. 
The distensibility coefficient of the carotid artery, and the carotid-femoral pulse wave 
velocity were measured during the third phase of the Rotterdam Study (1997-1999) 
and were used as measures of arterial stiffness. Data on both carotid stiffness and the 
ACE genotypes were available for 3001 participants. After adjustment for age and 
gender, subjects with the ID and DD genotypes had higher carotid stiffness compared 
with subjects with the II genotype. Distensibility coefficient (10–3/kPa) was 10.65 
(95% confidence interval (CI): 10.37, 10.93), 10.24 (95% CI: 10.06, 10.43), and 
10.27 (95% CI: 10.02, 10.52) for II, ID, and DD genotypes, respectively (p = 0.02 
for ID versus II, p = 0.04 for DD versus II). In stratified analyses, the association was 
stronger in subjects younger than 70 years. No differences were found for pulse wave 
velocity between the genotypes.
In conclusion, the results of this population based study show that the ACE ID and 
DD genotypes are associated with higher common carotid stiffness.
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Introduction 
One of the characteristics of the aging cardiovascular system is stiffening 
of the vessel wall. Arterial stiffness has been shown to be an independent 
predictor of cardiovascular morbidity and mortality in patients with  
essential hypertension1,2 and end-stage renal disease.3,4 This association may 
be explained by increased cardiac afterload,4,5 decreased coronary artery  
perfusion,6 and promotion of plaque rupture.7 Arterial stiffness increases with 
age,8 and is positively associated with hypertension,9,10 atherosclerosis,11,12 
diabetes mellitus,8 and end-stage renal disease.13 
Genetic factors may be involved in development of arterial stiffness. The 
angiotensin converting enzyme (ACE) gene has been implicated in structural 
changes of the vessel wall.14,15 The ACE gene has an insertion/deletion (I/D) 
polymorphism in intron 16, which has been previously found to be associated 
with cardiovascular diseases and atherosclerosis.16-19
Two previous studies20,21 reported a relationship between the ACE I  
allele and increased arterial stiffness in patients with hypertension and type 
2 diabetes, whereas no association was found in healthy controls. To our 
knowledge, only one study investigated the association between the ACE  
I/D polymorphism and arterial stiffness in a general population.22 The  
results of that study, which was conducted among young adults, suggest 
that the ACE D allele predisposes to a decreased compliance of elastic 
arteries. The aim of the present study is to assess the role of the ACE I/D 
polymorphism in determining arterial stiffness in a population based study 
among older adults.
 
Materials and methods
Study population
This study was conducted within the framework of the Rotterdam Study, 
an ongoing prospective population based cohort study among subjects 
aged 55 years or older, living in Ommoord, a suburb of Rotterdam, The 
Netherlands. The rationale and design of the Rotterdam Study have been 
described elsewhere.23 Baseline data were collected from 1990 to 1993. 
The third examination phase took place from 1997 to 1999. The Medical 
Ethics Committee of Erasmus University approved the study and written 
informed consent was obtained from all participants.
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Cardiovascular risk factors
Information on cardiovascular risk factors was collected during the third 
follow up examination. Data on medication use and smoking habits were 
obtained during the home interview. Participants were categorised as never, 
former, or current smokers.
At the research centre, blood pressure was measured twice on the right 
arm using a random-zero sphygmomanometer. The average of the two 
blood pressure values was used in the analyses. Hypertension was defined as a 
systolic blood pressure ≥ 160 mmHg and/or a diastolic blood pressure ≥ 100 
mmHg and/or the use of antihypertensive medication. Height and weight of 
the participants were measured and body mass index (kg/m2) was computed. 
Plasma total cholesterol and high density lipoprotein (HDL) cholesterol 
values were determined by an automated enzymatic procedure (Boehringer 
Mannheim System). Diabetes mellitus was defined as use of antidiabetic 
medication and/or a non-fasting plasma glucose level ≥ 11.1 mmol/L.
Arterial stiffness
Arterial stiffness was measured by two different methods, i.e. the  
distensibility coefficient of the common carotid artery as a measure of  
common carotid arterial stiffness and the carotid-femoral pulse wave  
velocity (PWV) as a measure of aortic stiffness. Both measures were  
obtained on the same day, in the same room. Subjects were instructed to 
refrain from smoking and from taking coffee, tea, or pain-related  
medications on the day of measurement, and from taking alcohol on the 
day of measurements and the day before. 
Common carotid distensibility was assessed with the participant in a  
supine position and the head tilted slightly to the left. The vessel wall  
motion of the right common carotid artery was measured by means of a 
duplex scanner (ATL Ultramark IV, operating frequency 7.5 MHz)  
connected to a vessel wall movement detector system. The details of this 
technique have been described elsewhere.24,25 After five minutes of rest, a 
region at 1.5 cm proximal to the origin of the bulb of the carotid artery 
was identified using B-mode ultrasound. The displacement of the arterial 
walls was obtained by processing the radio frequency signals originating 
from two selected sample volumes positioned over the anterior and posterior 
walls. The end-diastolic diameter (D), the absolute stroke change in diameter 
during systole (∆D), and the relative stroke change in diameter (∆D/D) were 
computed as the mean of four cardiac cycles of three successive recordings. 
Blood pressure was measured twice on the right arm with a Dinamap  
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automatic blood pressure recorder during the measurement session. The 
mean was taken as the subject’s reading. Pulse pressure (∆P) was defined as 
the difference between systolic and diastolic blood pressure. Mean arterial 
pressure was calculated by the following formula: 1/3 systolic blood pressure 
+ 2/3 diastolic blood pressure. The cross-sectional arterial wall distensibility 
coefficient was calculated according to the following equation: 
distensibility coefficient = (10–3/kPa).26 
In the present study, measurements were restricted to the right side to save 
time. In previous studies no differences could be detected between arterial 
wall properties of the right and left common carotid arteries (Samijo SK, 
unpublished results, 1997). 
Carotid-femoral PWV was measured with the subject in a supine  
position. Blood pressure was measured twice with a sphygmomanometer 
after five minutes of rest, and the mean was taken as the subject’s reading. 
Mean arterial pressure was calculated by the following formula: 1/3 systolic 
blood pressure + 2/3 diastolic blood pressure. Carotid-femoral PWV was 
assessed with an automatic device (Complior®, Colson)27 that measured 
the time delay between the rapid upstroke of the feet of simultaneously 
recorded pulse waves in the carotid and the femoral arteries. The distance 
between the carotid and the femoral arteries was measured over the surface 
of the body with a tape measure. PWV was calculated as the ratio between 
the distance travelled by the pulse wave and the foot-to-foot time delay  
and expressed in meters per second. The average of at least 10 successive  
measurements, to cover a complete respiratory cycle, was used in the analyses. 
In a reproducibility study in 47 subjects the intra-class correlation  
coefficient was 0.80 for both distensibility coefficient and carotid-femoral 
PWV.
Data description
Of the 4024 subjects who underwent the physical examination of the 
third phase of the Rotterdam Study, PWV was measured in 3447 subjects 
whereas common carotid distensibility was measured in 3098 subjects. 
Missing information on measures of arterial stiffness was almost entirely 
due to logistic reasons. Information on PWV measurements and the ACE 
gene polymorphism were available for 3406 subjects, and information for 
both common carotid distensibility and the ACE gene polymorphism were 
available for 3001 participants.
2 ∆D ∆PD
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Laboratory assessments
The II, ID, and DD genotypes were determined at baseline, with blood 
samples, by the polymerase chain reaction technique (PCR) using a 
PE9600 PCR machine according to the method of Lindpaintner et al 28 
with some modifications. The result of amplification was a 319 bp and a 
597 bp amplicon for the D and the I alleles, respectively. Because the D 
allele in heterozygous samples is preferentially amplified, there is a tendency 
towards misclassification of about 4 to 5 percent of ID genotype to DD. In 
order to avoid this, a second independent PCR was performed with a primer 
pair that recognises an insertion specific sequence. The reaction yielded a 
335 bp amplicon only if the I allele was present. In the post-PCR analyses, 
10 µl of PCR product was loaded onto a 3% agarose gel. Two independent 
investigators interpreted the pictures from each gel and all ambiguous  
samples were analysed a second time.
Statistical analyses
ACE I/D polymorphism was tested as a three class variable (presence of 
0, 1, or 2 D alleles). The Hardy-Weinberg equilibrium was tested by a 
chi-square test. General characteristics were compared between men and 
women using student t-test for continuous variables and chi-square test  
for dichotomous variables. The association between the ACE genotype  
and arterial stiffness was next investigated by analysis of variance after  
adjustment for potential confounding variables. Subsequently, analyses were 
conducted in strata of age, gender, hypertension, body mass index, diabetes 
mellitus, and smoking status. Two categories of age were defined; subjects 
younger than 70 years, and subjects aged 70 years or older. The median 
value of body mass index (26.7 kg/m2) was used to define two strata. Linear 
regression analysis was used to test interaction between age and the ACE 
genotype. 
Results
Characteristics of the study subjects (3001 subjects with common carotid 
distensibility measurement) are presented in Table 1. The distribution 
of the ACE genotypes was consistent with Hardy-Weinberg equilibrium. 
None of the traits differed significantly between those with and without a 
successful genotype. 
Subjects with the ID and DD genotypes had a higher stiffness of the 
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common carotid artery compared with subjects with the II genotype, while 
no difference was found between the ID and DD genotypes (Table 2). 
Pulse wave velocity was not different between the three genotype groups 
(Table 2).
In analyses stratified for age (Figure 1), 1308 subjects were younger than 
70 years and 1693 subjects were aged ≥ 70 years. Subjects younger than 70 
years with the ID and DD genotypes had higher stiffness of the common 
carotid artery compared with subjects with the II genotype after adjustment 
for age, gender, mean arterial pressure and heart rate. The distensibility 
coefficients of II, ID, and DD genotypes were 12.48 (95% confidence 
interval (CI): 12.11, 12.84), 11.90 (95% CI: 11.64, 12.16) and 11.96 
(95% CI: 11.62, 12.31), respectively. The interaction between age and the 
ACE I/D polymorphism was statistically significant (p for interaction was 
0.04). When we adjusted for total and HDL cholesterol, smoking, body 
mass index, and diabetes mellitus, results maintained statistically significant. 
Table 1. Demographic characteristics of the study population 
Men (n = 1263) Women (n = 1738)
Age (years) 71.71 ± 6.50 72.18 ± 6.93*
Body mass index (kg/m2) 26.17 ± 3.20 27.12 ± 4.38*
Systolic BP (mmHg) 134.14 ± 19.19 132.14 ± 19.66*
Diastolic BP (mmHg) 73.99 ± 9.42 67.76 ± 9.38*
Mean arterial pressure (mmHg) 94.03 ± 11.44 89.22 ± 11.51*
Heart rate (beat/m) 71.69 ± 12.68 74.62 ± 11.56*
Hypertension (%)† 33.80 36.36
Total cholesterol (mmol/L) 5.54 ± 0.95 6.06 ± 0.96*
HDL cholesterol (mmol/L) 1.25 ± 0.33 1.51 ± 0.41*
Current smoking (%) 18.13 14.27*
Diabetes mellitus (%) 7.81 6.85
Distensibility coefficient (10–3/kPa) 10.94 ± 4.21 9.91 ± 4.01*
Pulse wave velocity (m/s) 13.91 ± 3.11 13.06 ± 2.88*
ACE D allele (%) 52.10 53.89
Continuous values are mean ± standard deviation. 
ACE: angiotensin converting enzyme gene; BP: blood pressure; HDL: high density lipoprotein.
* p < 0.05 compared with men.
† Hypertension, defined as systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg or  
medication use.
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We did not find any difference in carotid stiffness between genotypes in 
the subjects aged ≥ 70 years. In analyses stratified for gender, hypertension, 
body mass index, diabetes mellitus, and smoking habits, no differences in 
the effect of the genotype on stiffness were seen between the strata (data 
not shown). 
Discussion
In this population based study we found that the presence of the ACE ID 
and DD genotypes was associated with higher stiffness of the common  
carotid artery. The association was stronger in subjects younger than 70 
years old and no longer present in the older age category. No relation was 
found between the ACE genotype and arterial stiffness measured by  
carotid-femoral pulse wave velocity.
Table 2.  Distensibility coefficient of common carotid artery and carotid-femoral 
PWV according to the ACE genotypes
ACE genotype p (ANOVA)
Distensibility coefficient, mean (95% CI)
II (n = 675) ID (n = 1508) DD (n = 818)
Model A 10.65 (10.37, 10.93) 10.24 (10.06, 10.43)* 10.27 (10.02, 10.52)* 0.05
Model B 10.58 (10.34, 10.82) 10.24 (10.08, 10.40)* 10.33 (10.11, 10.54) 0.06
Model C 10.62 (10.38, 10.86) 10.28 (10.12, 10.44)* 10.35 (10.13, 10.57) 0.03
PWV, mean (95% CI)†
II (n = 777) ID (n = 1704) DD (n = 925)
Model A 13.45 (13.26, 13.65) 13.53 (13.40, 13.66) 13.57 (13.39, 13.74) 0.73
Model B 13.50 (13.33, 13.68) 13.56 (13.44, 13.67) 13.49 (13.33, 13.65) 0.99
Model C 13.51 (13.34, 13.69) 13.48 (13.37, 13.60) 13.50 (13.34, 13.66) 0.69
Model A includes age and gender.
Model B includes age, gender, heart rate, and mean arterial pressure.
Model C includes age, gender, heart rate, mean arterial pressure, body mass index, diabetes mel-
litus, total and HDL cholesterol, and smoking.
ACE: angiotensin converting enzyme gene; ANOVA: analysis of variance; CI: confidence interval; 
HDL: high density lipoprotein; PWV: pulse wave velocity. 
* p < 0.05 compared with II genotype. 
† PWV measurements were available for 3406 subjects.
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Some aspects of this study need to be discussed. Information on arterial 
stiffness was not available for all participants which was primarily due to 
logistic reasons. Therefore, we conclude that this will not have biased the 
results. Secondly, by calculating the distensibility coefficient, distension 
of the common carotid artery is adjusted for pulse pressure measured in 
the brachial artery. We thereby assume that pulse pressure measured in the 
brachial artery is representative of pulse pressure in the carotid arteries. In 
dogs it has been demonstrated that pulse pressure in the brachial artery 
is linearly related to pulse pressure in the carotid artery over a wide range 
of blood pressure. However, it is known that the arterial pressure waves 
undergo transformation in the arterial tree and therefore the pulse pressure 
is higher in the brachial artery than in more central vessels like the carotid 
artery. On the other hand, non-invasive cuff-based measurement of blood 
pressure underestimates pulse pressure. Several investigators compared 
non-invasively measured elastic arterial properties and showed the validity 
of brachial pressure to measure pulse pressure.29,30 Thirdly, the distensibility 
coefficient has a strong correlation with mean arterial pressure. A higher 
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Figure 1.  Distensibility coefficient of the common carotid artery in different 
genotypes stratified by age categories 
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Data are adjusted for age, gender, mean arterial pressure, and heart rate. 
* Significantly different from the genotype II < 70 years group. 
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mean arterial pressure in the artery stretches the elastin and collagen fibres 
in the arterial wall, making the arteries less distensible. Consequently, we 
repeated the analysis after adjustment for mean arterial pressure.
Our results are in agreement with the results of a previous study, which 
showed that higher stiffness of the common carotid artery was associated 
with the ACE D allele in a small group of young adults.22 Two other studies 
assessed the involvement of the ACE I/D polymorphism in arterial  
stiffness.20,21 Benetos et al 20 reported that aortic stiffness, assessed by 
measuring aortic pulse wave velocity, was similar among the three ACE I/D 
genotypes in normotensive subjects, whereas it was slightly higher among 
hypertensive subjects with the II genotype. Taniwaki et al 21 reported that 
the I allele of the ACE gene was associated with stiffness of the large  
arteries, such as the carotid artery and the aorta in patients with type 2 
diabetes. In our study, the sample was definitely too small to see significant 
differences among strata of blood pressure and diabetes mellitus. We found 
that the association was stronger in subjects younger than 70 years and no 
longer present in the older age category.
We found no association between the ACE genotype and carotid-femoral 
pulse wave velocity. The measure of carotid distensibility is a local measure 
of stiffness that gives information on an elastic artery, while carotid-femoral 
pulse wave velocity reflects arterial stiffness of several territories providing 
information on both elastic and muscular arteries. There may be differences 
between various types of arteries with respect to the contribution of each of 
these components, and genetic determinants may have a different outcome 
according to the type of artery studied. It has been shown that in elastic  
arteries, hypertrophy of the wall is predominantly due to intima thickening, 
whereas in muscular arteries this phenomenon mainly reflects remodelling 
of the media,31 which might consequently induce primarily an increased 
distensibility of the muscular arteries. We cannot exclude that the difference 
in findings for the distensibility coefficient and pulse wave velocity is due to 
differences in the validity or reproducibility of the measurement. The  
validity of both the distensibility coefficient and pulse wave velocity has 
been shown in studies that examined associations of these measures with 
cardiovascular risk factors and cardiovascular diseases.1,2,8,10,12 We found that 
the reproducibility of both measures was adequate. Therefore, we do not 
think that this is a likely explanation for our results. 
The mechanisms that may modulate the relation between the ACE gene 
and arterial stiffness are not completely clear. Higher circulating and tissue 
ACE levels are present in subjects with the D compared with the I allele.32-34  
ACE catalyses the conversion of angiotensin I to angiotensin II and the 
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breakdown of bradykinin to kinin degradation products. Both angiotensin 
II and bradykinin are potent peptide hormones that play a role in vascular 
wall homeostasis, vascular tone, vascular smooth muscle cell growth, and 
production of extracellular matrix.35-38 These processes may then lead to 
progressive degeneration of arterial media with fractures and fragmentation 
of elastic lamellae, increased collagen and calcium content and dilation and 
hypertrophy of the large arteries with subsequent increased arterial stiffness. 
Hence, chronic exposure to high levels of circulating and tissue ACE 
may predispose to increased arterial stiffness. Finally, it has been shown 
that treatment with ACE inhibitors may increase vascular compliance and 
thereby reduce arterial stiffness, independently from blood pressure levels. 
The results confirm the role of ACE in the development of arterial stiffness.
In summary, the results of our population based study show that the 
presence of the ACE ID and DD genotypes was associated with higher  
stiffness of the common carotid artery. The association was stronger in 
subjects younger than 70 years old.
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Chapter 4 
The ACE I/D polymorphism and 
clinical outcomes
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Chapter 4.1 
The ACE I/D polymorphism and 
cardiovascular morbidity and mortality: 
   the Rotterdam Study
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Abstract
Findings on the association between the insertion/deletion (I/D) polymorphism of 
the angiotensin converting enzyme (ACE) gene and cardiovascular morbidity and 
mortality have been inconsistent. Considering the possible interaction between this 
polymorphism and smoking, we evaluated the association between the ACE I/D 
polymorphism and myocardial infarction (MI), and mortality due to coronary heart 
disease (CHD) and cardiovascular diseases (CVD).
The study was performed within the Rotterdam Study, a population based cohort 
study that started in 1990. The ACE I/D polymorphism was determined for 6714 
participants, and smoking status recorded at baseline. Fatal and non-fatal MIs and 
mortality events were regularly recorded. Cox proportional hazards analysis was 
performed separately for current smokers and non-/former smokers. We used age as 
the follow up time in the model, presenting age specific survivals. 
During follow up 248 MIs, and 301 and 482 deaths, respectively, due to CHD 
and CVD occurred. There were no significant differences between the genotypes in 
relation to incidence of MI. Among smokers, there was an increased risk of CHD 
and CVD mortality in carriers of the DD genotype compared with the II genotype, 
which diminished at later ages (p value < 0.01 for gene-age interaction). Subgroup 
analyses in younger and older groups (based on the median age of 68.2 years) showed 
a significantly increased risk of CVD mortality in the younger group (hazard ratio = 
5.19; 95% confidence interval: 1.15, 23.42). 
This study showed that the ACE I/D polymorphism is not a strong risk factor for 
MI, but its interaction with smoking might play a role in mortality from cardiovascular 
diseases, especially at younger ages. 
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Introduction
The insertion/deletion (I/D) polymorphism in intron 16 of the angiotensin 
converting enzyme (ACE) gene has been associated with myocardial infarction 
(MI)1,2 and coronary heart disease (CHD).3,4 However, the findings of  
various large studies have been inconsistent. This situation is typical for  
genetic research of complex diseases, where genes may be involved in a 
disease through complex interactions with other genes and environmental 
factors. Using all the data we had available in the Rotterdam Study, we 
searched for modifiers of the relation between the ACE gene and plasma 
ACE levels and found that smoking is the only other factor significantly 
influencing plasma ACE activity level.5 Further, we found interaction 
between the ACE polymorphism and smoking in relation to carotid intima 
media thickness (IMT),5 as well as systolic blood pressure.6 These findings 
prompted us to evaluate the effect of the ACE gene on MI as the main  
morbidity outcome of CHD, taking into account the putative interaction  
with smoking. We also investigated the association between the gene and 
mortality due to CHD, as well as mortality from cardiovascular diseases 
(CVD). We conducted our study in a large cohort, which has been  
characterised for CVD and has been followed for over 8 years, allowing us 
to assess the genotype associations at different ages.
 
Materials and methods
Study population
This study is embedded in the Rotterdam Study, a prospective population 
based cohort study of 7983 men and women aged 55 years or older, living 
in Ommoord, a suburb of Rotterdam, The Netherlands. The study is  
designed to investigate the determinants of chronic diseases in the elderly 
and has been described in more detail elsewhere.7 Baseline data were  
collected between March 1990 and July 1993. The study was approved by 
the Medical Ethics Committee of Erasmus University, and written informed  
consent was obtained from all participants. A trained research assistant 
interviewed all participants at home using computerised questionnaires. 
The information obtained included current health status, medical history, 
medication use, and smoking behaviour. In addition, during two visits to 
the research centre, established cardiovascular risk factors were measured. 
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Follow up procedures
The present analyses on MI and CHD mortality are based on follow up 
data collected from baseline (1990-1993) until January 1, 2002. The  
information on cause specific mortality was obtained until January 1, 2000, 
and was the source of data on CVD mortality outcome. Information on 
the vital status of the participants was obtained at regular intervals from the 
municipal population registry. Fatal and non-fatal MIs were reported by 
general practitioners in the research area by means of a computerised  
system. An MI was considered fatal if death occurred within 28 days after 
the onset of symptoms. In the case of recurrent MI during follow up, the 
first event was used in the analyses. All reported events were verified by  
research physicians who collected information from the patients’ medical 
records. This information also included copies of discharge letters for  
hospital admissions. All events were coded independently by two research 
physicians according to the International Statistical Classification of Diseases 
and Related Health Problems, 10th revision (ICD-10).8 CHD mortality is 
defined as ICD codes I20-I25, I46, I50, and R96. CVD mortality includes 
all CHD deaths plus deaths due to stroke (I60-I64).
Laboratory assessments 
Blood samples were drawn and serum and plasma were stored at –80 °C. 
DNA was isolated from blood samples using a standard procedure (the  
salting out method)9 and the II, ID, and DD genotypes were detected  
using the polymerase chain reaction technique according to the method of 
Lindpaintner et al 10 with some modifications. Details of the genotyping 
method were published previously.5
Statistical analyses
Data were analysed using SPSS version 11.0 and S-PLUS version 6.0 for 
Windows. Hardy-Weinberg equilibrium was tested with the chi-square test. 
We used smoking as a dichotomous variable, grouping subjects in current  
smokers or non-/former smokers. Survival time was calculated as the 
number of years from entry into the study until the time of the first event 
or until the end of follow up, whichever came first. We used Kaplan-Meier 
curves with age as the follow up time in the model, presenting age specific 
survivals. Cox proportional hazards analysis was used to calculate the hazard 
ratios between the genotype groups using the II genotype as the reference 
group. Data were analysed separately for current and non-/former smokers 
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to examine effect modification by smoking. We also examined our  
hypothesis in gender subgroups, as one may expect differences between 
genders regarding the causal chain leading to CVD. Possible interactions 
were tested using multiplicative models.
 
Results
The complete data of the ACE genotypes and smoking status were  
available for 6714 subjects. Missing data were mainly due to logistic 
reasons. The distribution of the genotype and allele frequencies were in 
Hardy-Weinberg equilibrium (p = 0.74). Table 1 shows the demographic 
characteristics of the participants by the ACE genotypes. The carriers of 
the D allele were somewhat older than the II carriers. Carriers of the DD 
genotype had a significantly higher mean systolic blood pressure as well as 
Table 1.  Demographic characteristics of subjects according to the ACE I/D 
genotypes
ACE genotype
II (n = 1473) ID (n = 3358) DD (n = 1883)
Age (years) 68.79 ± 9.15 69.46 ± 8.97* 69.50 ± 9.23*
Male gender (%) 41.07 40.59 39.56
Body mass index (kg/m2) 26.34 ± 3.84 26.26 ± 3.72 26.35 ± 3.66
Current smoking (%) 22.81 23.17 20.92
Total cholesterol (mmol/L) 6.58 ± 1.26 6.62 ± 1.20 6.60 ± 1.22
HDL cholesterol (mmol/L) 1.34 ± 0.36 1.35 ± 0.35 1.35 ± 0.37
Systolic BP (mmHg) 138.33 ± 22.08 139.32 ± 22.66 140.17 ± 22.14*
Diastolic BP (mmHg) 73.60 ± 11.78 73.69 ± 11.69 73.96 ± 11.29
Hypertension (%)† 31.75 35.24* 34.71
Prevalence MI (%)‡ 11.52 13.24 12.27
Common carotid IMT (mm×10–1) 7.89 ± 1.53 7.99 ± 1.59 8.03 ± 1.59*
Continuous values are mean ± standard deviation. 
ACE: angiotensin converting enzyme gene; BP: blood pressure; HDL: high density lipoprotein; 
I/D: insertion/deletion; IMT: intima media thickness; MI: myocardial infarction. 
* p < 0.05 compared with II genotype. 
† Hypertension, defined as systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg or  
medication use. 
‡ Myocardial infarction, verified by cardiologist, general practitioner or electrocardiogram. 
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an increased mean of carotid IMT compared with the II carriers. Although 
the prevalence of hypertension was increased in both homozygote and het-
erozygote subjects for the D allele, this increase was significant only in the 
largest group, the heterozygotes. There was a tendency of higher prevalence 
of MI in carriers of the D allele, but the difference was not statistically 
significant (Table 1). We excluded the subjects with prevalent MI in our 
further analyses as differential mortality may have occurred in this sub-
group before the start of the study. 
Mean follow up time for CVD was 8.4 years. During this period 248 
persons had a first MI and 301 deaths due to CHD occurred. For the 
period of follow up for CVD mortality outcome (mean = 7.1 years) 482 
deaths caused by CVD occurred. Table 2a presents the age and gender  
adjusted incidence rates by genotypes. No obvious pattern was observed in 
the association between the genotypes and the risk of MI. Among smokers, 
the incidence rates for CHD and CVD mortality were higher in carriers 
of the DD genotype, while no such differences were seen in non-/former 
smokers. However, the differences in incidence rates between the genotypes 
were not statistically significant (Table 2a). Further analyses, stratified by 
gender, did not reveal any evidence for increasing incidence rates associated 
with genotype in men or women (Table 2b)
Table 3. Test of interaction between the ACE I/D genotypes, smoking status, and age 
CHD mortality CVD mortality
ID DD ID DD
Gene-age interaction*
p (smokers) 0.01 < 0.01 < 0.01 < 0.01
p (non-/former smokers) 0.75 0.58 0.63 0.15
p (total group) 0.24 0.20 0.39 0.32
Gene-smoking interaction†
p (below median of age)‡ 0.13 0.06 0.24 0.05
p (above median of age)‡ 0.46 0.83 0.65 0.98
p (total group) 0.27 0.42 0.50 0.39
The II genotype is used as the reference group.
ACE: angiotensin converting enzyme gene; CHD: coronary heart disease; CVD: cardiovascular 
diseases; I/D: insertion/deletion.
* Adjusted for gender. 
† Adjusted for age and gender.
‡ Median age = 68.2 years 
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Figure 1.  Age specific CHD mortality for different genotype groups in smokers 
(top) and non-/former smokers (bottom) 
Data are adjusted for gender.
CHD: coronary heart disease. 
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Figure 2.  Age specific CVD mortality for different genotype groups in smokers 
(top) and non-/former smokers (bottom)
Data are adjusted for gender.
CVD: cardiovascular diseases.  
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When considering age specific mortality (Figures 1 and 2), an increased risk 
of CHD and CVD mortality in the DD genotype group was observed only 
in smokers. The effect of the gene diminished with age. No such effect was 
seen in non-/former smokers (Figures 1 and 2). The interaction between  
the ACE genotype and age was statistically significant in smokers (p < 0.01), 
but not in non-/former smokers or the total group (Table 3). The same  
pattern of genotype-age interaction was observed in both men and women. 
No interaction between the genotype and gender was observed in any of 
the smoking categories (data not shown). 
With this observation, we retested our hypothesis separately for the 
groups younger and older than the median age of the population (68.2 
years) using the age as a time dependent variable, that is, when a participant 
in the younger group reached the age of 68.2 he was counted in the older 
group. Table 4 presents the hazard ratios of CHD and CVD mortality for 
the ID and DD genotypes in comparison to the II genotype in different 
subgroups. In the younger group, the risk of CVD mortality showed a 
significant difference between the genotypes in smokers (p = 0.03) but not 
in non-/former smokers (p = 0.60), men (p = 0.25) or women (p = 0.45). 
Higher risk of mortality was observed in those with the ID and DD  
genotypes compared with the II genotype among smokers in this group 
(Table 4). A multiplicative model for gene-smoking interaction showed 
borderline significance (p = 0.06) in CHD mortality and significance  
(p = 0.05) in CVD mortality among the younger group (Table 3). There 
was no evidence of association between the genotypes and the mortality 
risks in the older group in any of the smoking or gender categories (Table 4). 
 
Discussion
In this large population based cohort study, we observed an increased risk 
of cardiovascular mortality for carriers of the D allele of the ACE I/D  
polymorphism among smokers. This difference was only observed in 
younger people and diminished at later ages. No association was observed 
between the ACE genotype and MI. 
The ACE gene became one of the most studied candidate genes in  
relation to CVD after Rigat et al 11 reported that more than half of the 
variance of plasma ACE concentration is under the influence of the I/D 
polymorphism in this gene. Although several studies showed a positive  
association between the D allele and cardiovascular outcomes, findings  
have been inconsistent. A meta-analysis showed that smaller studies tend  
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to show a stronger association and concluded that in general the association 
is weak.12 However, interactions between genetic and environmental factors  
are expected in all complex diseases and may partly explain the previous  
inconsistencies. A possible interaction between smoking and the I/D 
polymorphism in relation to carotid IMT5 and systolic blood pressure6 
prompted the present study to test the same interaction effect on the risk 
of MI as the main morbidity outcome of CHD, as well as mortality due to 
CHD and CVD.
Our findings in this cohort study were in line with the findings from 
other large studies,10,13,14 showing no strong association between the ACE 
I/D and MI. Hibi et al 15 showed a smoking associated effect of the ACE 
genotype on the severity of coronary atherosclerosis. Although we  
confirmed the same interaction in our previous findings,5,6 we did not  
observe any evidence for such an interaction in relation to MI in this study. 
Considering mortality, the main differences between the genotypes were 
observed at earlier ages in our population. At older ages, the effect of the 
gene apparently diminished. One may argue that the older individuals are 
the survivors from a larger cohort and have been subject to selective  
mortality.16 We previously reported an interaction between age and the 
ACE I/D genotype in association with carotid stiffness.17 An age dependent 
association has also been found in the other genes involved in CVD, for 
instance apolipoprotein E.18,19 Although chance might play a role in our  
observations, the possibility remains that the interaction between the D 
allele and smoking in fact has a role in younger age groups, but we are 
not able to fully demonstrate it in our study population. In other words, 
if there is a real effect of the D allele and smoking at young ages, it might 
very well have happened before the start of our study, which only includes a 
cohort aged 55 years or older. 
The mechanism by which the ACE I/D polymorphism may affect  
cardiovascular morbidity and mortality is unclear. It has been shown that 
the DD carriers convert angiotensin I at higher rates.20,21 The vasoconstrictor 
effect of angiotensin II in addition to its role in vascular smooth muscle cell 
growth and hypertrophic changes of the vessel walls22,23 were speculated to 
be the possible pathway. It is also suggested that ACE might play an  
important role in inflammatory responses.24 Furthermore, smoking increases 
ACE gene expression and the activity levels of the enzyme.5,25,26 Considering 
the complexity of CVD, a combination of several different pathways could 
be involved in the present observations and the mechanisms involved in 
cardiovascular events at younger ages could be different from those in later 
life. Similarly, differences in causal chains in different samples could be the 
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main reason for controversial findings, but discovery of the whole underlying 
system is beyond the scope of a single observational study.
In conclusion, our study showed that the I/D polymorphism of the ACE 
gene is not a strong risk factor for myocardial infarction but its interaction  
with smoking might play a role in mortality from the cardiovascular diseases, 
especially at an earlier age. 
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Chapter 4.2 
The ACE I/D polymorphism and 
total mortality: 
the Rotterdam Study
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Abstract
Genetic and environmental risk factors that may influence longevity and mortality 
have received considerable attention over the last few decades. One of the major 
risks for mortality is cardiovascular diseases and the renin angiotensin system 
plays a major role in maintaining blood pressure homeostasis. In this system, the 
angiotensin converting enzyme (ACE) is one of the key regulators and has been 
studied with respect to cardiovascular diseases and mortality. In order to evaluate 
the ACE insertion/deletion (I/D) polymorphism and its relationship to overall 
mortality, 6968 elderly individuals from the Rotterdam Study were genotyped for the 
this polymorphism. Smoking was studied as a possible effect modifier. To examine 
the effect of the ACE genotype on mortality, a Cox proportional hazards model was 
fitted. Our results show an increased risk of overall mortality (hazard ratio = 1.8; 
95% confidence interval: 1.1, 2.9; p = 0.02) in subjects with an age at death below 
65 years in carriers of the DD genotype. This association was significant only in 
those who smoke. Our findings suggest that the ACE gene is associated more with 
early mortality than with late. Individuals who carry the DD genotype appear to be 
susceptible to early mortality if they smoke, suggesting a possible interaction between 
smoking and the ACE gene. 
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Introduction
The insertion/deletion (I/D) polymorphism in the angiotensin converting 
enzyme (ACE) gene has been studied extensively with respect to cardiovascular 
diseases and mortality. The D allele has been consistently related to higher ACE  
levels.1-3 Even though findings have been inconsistent, the large majority of 
studies suggest the D allele of the ACE gene is associated with atherosclerosis,3,4  
and an increased risk of cardiovascular diseases.5,6 The contribution of the gene 
to mortality remains a matter of debate. Some studies found an increased risk 
of mortality for carriers of the D allele,7,8 others for carriers of the I allele,9 
while a substantial number of studies found no effect.10,11 Recently, we found 
that smoking and the ACE gene are both associated with plasma ACE levels 
and may interact in the process of atherosclerosis.3,12 These findings triggered the 
present study to examine the role of the ACE gene in mortality and longevity,  
utilizing smoking as a potential modifier of the effect of the ACE gene.
Materials and methods
Study population
Our study is part of the Rotterdam Study,13 a population based follow up  
study of determinants of diseases in the elderly. All inhabitants of Ommoord,  
a suburb of Rotterdam, aged 55 years or older, were invited to participate. 
The design of the study has been previously described.13 From all subjects, 
informed consent was obtained and the Medical Ethics Committee of the 
Erasmus University approved the study. 7983 participants were examined at 
baseline (1990-1993). Information on age, smoking behaviour and medical  
history were obtained using a computerised questionnaire. Two blood  
pressure measurements were taken in a sitting position on the right arm 
using a random-zero sphygmomanometer. The average of the two measures 
was used in the analyses. Information on all-cause mortality was collected 
through February 3, 2003. 
Laboratory assessments
The ACE I/D polymorphism was genotyped in 6869 subjects of the Rotterdam 
Study (86%). DNA was isolated from blood samples using a standard 
procedure (the salting out method).14 The II, ID, and DD genotypes were 
detected using the polymerase chain reaction technique according to the 
method of Lindpaintner et al 15 with some modifications.3 
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Statistical analyses
Hardy-Weinberg equilibrium of the I/D polymorphism was tested with the 
chi-square test. Frequencies of mortality and smoking status in the different  
genotype groups were compared using the chi-square test. Differences in 
age and blood pressure between genotype groups were tested using the 
Kruskal-Wallis non-parametric test for independent samples. To examine 
the effect of the ACE genotype on mortality, a Cox proportional hazards 
model was fitted, taking the II genotype as the reference category. We used 
age as the underlying time of the model. Analyses were subsequently stratified  
for age (55-64.9 years, 65-74.9 years, 75-84.9 years, and ≥ 85 years of 
age) and smoking status (current and non-/former smoker). The statistical 
analyses were carried out using SPSS version 11.0 for Windows. Survival 
curves were plotted using S-PLUS version 6.0 for Windows.
Results
Table 1 presents the characteristics of the DD, ID, and II genotypes. The 
distributions of the genotype and allele frequencies were in Hardy-Weinberg 
equilibrium (p = 0.70). No significant differences between the genotype 
groups were found in mean age at entry, smoking status, or diastolic blood 
pressure. Mean systolic blood pressure was higher in the DD carriers  
compared with the II carriers (p = 0.02). Overall, mortality was increased 
in the DD carriers but not significantly. Figure 1 shows the age specific 
survival curves by the ACE genotypes adjusted for gender. The DD carriers  
had slightly increased mortality compared with the II carriers at early age. 
Stratified analyses by age categories showed that mortality for subjects 
with ages below 65 years at baseline carrying the DD genotype was 1.5-fold 
increased (95% confidence interval (CI): 1.1, 2.1; p = 0.01) during 10 
years of follow up. In Figure 2, the survival curves by the ACE genotypes 
for smokers and non-/former smokers are shown. In the former group, the 
risk of mortality was significantly increased throughout life (p = 0.03). The 
risk of mortality for the DD compared with the II carriers was increased 
1.3-fold (95% CI: 1.0, 1.6), while in non-/former smokers there was no 
evidence for an effect of the ACE (Figure 2). Among smokers, the effect of 
the ACE gene was strongest early in life; the risk for the DD carriers aged 
below 65 years who smoke was 1.8 (95% CI: 1.1, 2.9) times higher than in 
subjects carrying the II genotype in the same age and smoking categories. 
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Table 1.  Demographic characteristics of the study population according to the 
ACE I/D genotypes
ACE genotype
II (n = 1513) ID (n = 3429) DD (n = 1927)
Age (years) 69.07 ± 9.30 69.60 ± 9.03 69.72 ± 9.40
Male gender (%) 40.52 40.30 39.28
Current smoking (%) 22.81 23.17 20.92
Systolic BP (mmHg) 138.44 ± 21.98 139.22 ± 22.64 140.20 ± 21.16*
Diastolic BP (mmHg) 73.64 ± 11.81 73.67 ± 11.70 73.90 ± 11.29
Mortality during follow up (%) 32.45 33.13 35.13
Continuous values are mean ± standard deviation. 
ACE: angiotensin converting enzyme gene; BP: blood pressure; I/D: insertion/deletion. 
* p < 0.05 compared with II genotype. 
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Figure 1. Survival curve for the ACE I/D genotype groups 
Data are adjusted for gender.
ACE: angiotensin converting enzyme gene; I/D: insertion/deletion. 
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Figure 2.  Survival curve for the ACE I/D genotype groups in smokers (top) and 
non-/former smokers (bottom) 
Data are adjusted for gender.
ACE: angiotensin converting enzyme gene; I/D: insertion/deletion. 
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Discussion
In our study of 6896 elderly participants of the Rotterdam Study we 
found an increased risk of mortality at early age for carriers of the DD 
genotype. This association was significant only in smokers. Although the 
risk of mortality for the DD carriers compared with carriers of the other 
genotypes was highest at early age, the increased risk of mortality also 
persisted later in life.
Several studies have addressed the role of the ACE gene on mortality 
but findings have been inconclusive. Our findings are at odds with another 
large cohort study embedded within the Copenhagen City Heart Study  
including 10,150 individuals.10 They could not show a relationship  
between the ACE DD genotype and cardiovascular mortality or longevity. 
However, they did not stratify for smoking but merely adjusted for it. In 
addition, a large study of French centenarians (n = 563) failed to show 
an association between the ACE genotype and longevity.11 In contrast, 
another study showed that the DD variant of ACE was more frequent in 
centenarians compared with younger healthy controls.16 Our results suggest 
that mortality related to the ACE gene is dependent on age. We found a 
particularly increased risk of early mortality in carriers of the D allele. 
The relationship between the ACE gene and mortality at different ages 
may not be similar. The ACE gene might be an important risk factor in 
causal pathways leading to early mortality, while not playing a significant 
role later in life. A plausible explanation for the interaction between ACE 
and smoking in early mortality could be a smoking dependent effect of 
ACE on vascular homeostasis. We found the effect of the D allele on  
atherosclerosis was smoking dependent.3 In that study, smoking was the 
only cardiovascular risk factor associated with ACE levels together with the 
ACE gene. Although chance might play a role in these observations, our 
findings are in line with a study which demonstrated a synergistic effect of 
smoking and the ACE DD genotype on coronary artery disease.17  
Moreover, a smoking dependant association has also been found in other 
genes involved in vascular pathophysiology.18 
In conclusion, our findings support a role for the ACE I/D  
polymorphism in increasing the risk of mortality at early ages that is 
prominent in smokers, providing evidence of a gene-environment  
interaction.
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Chapter 4.3 
The ACE I/D polymorphism and 
co-morbidity effect: 
the Rotterdam Study
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Abstract
There is increasing evidence that atherosclerosis is not only involved in cardiovascular 
diseases (CVD) but also other diseases of the elderly such as Alzheimer’s disease 
(AD). Since CVD are highly fatal and usually occur earlier than Alzheimer’s 
disease, the co-morbidity by CVD might hamper studies on the association between 
atherosclerosis risk factors and AD. Here we used the inverse probability of censoring 
weighted analyses method to test this hypothesis, in a study on the relationship 
between the insertion/deletion polymorphism of the angiotensin converting enzyme 
gene (ACE I/D) and risk of AD. 
We used data from the Rotterdam Study, a prospective population based study. We 
first performed a Cox proportional hazards model including all available cardiovascular 
risk factors to calculate the probability of death from CVD and thereby the probability 
of being free from fatal CVD events. These probabilities were then used to weight 
the subjects who were uncensored by fatal disease by the inverse of their survival 
probability. In a weighted analysis we estimated the association between the ACE I/D 
polymorphism and AD. 
Among 2431 men that were free from Alzheimer’s disease at baseline, 51 persons 
were diagnosed for AD and 196 individual had fatal cardiovascular events without 
occurrence of AD during the follow up. Among 3281 women, these numbers were 89 
and 159, respectively. Survival analyses showed that the association between the I allele 
and AD was mainly present in women (p values for trend was 0.09). In the weighted 
analyses the hazard ratios did not materially change in any of the gender groups. 
Our results indicate that the association between the I allele of the ACE gene and 
Alzheimer’s disease is not due to the co-morbidity effect of CVD. 
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Introduction
There is increasing evidence that atherosclerosis is not only an etiologic  
factor for cardiovascular diseases (CVD), but also for other complex diseases 
of the elderly such as Alzheimer’s disease (AD).1-3 In an observational study, 
those who died during follow up from CVD may have been at higher 
risk of developing Alzheimer’s disease compared with the survivors in the 
population. Therefore, studies on the etiological role of atherosclerotic risk 
factors in AD might be hampered, since CVD is highly fatal and usually 
occurs at earlier ages than the former disease. 
The insertion/deletion polymorphism of the angiotensin converting  
enzyme gene (ACE I/D) is a risk factor for both CVD and AD. Although  
individual studies were inconsistent, several meta-analyses indicated that the 
D allele of this polymorphism is a risk factor for atherosclerosis4 and increases 
the risk of CVD.5,6 However, the findings on the association between this 
polymorphism and AD showed a different pattern. It has been reported that 
the I allele of the I/D polymorphism might increase the risk of Alzheimer’s 
disease7,8 and this finding has been confirmed by subsequent meta-analyses.9-11 
In a case-control study, Kehoe et al 7 suggested that the low frequency of the 
DD genotype in AD patients might have been due to the exclusion of cases 
due to cardiovascular mortality before the start of the study. 
In this study, we implemented a methodology to adjust for the effect of 
co-morbidity, which has been used previously to correct for non-compliance  
and dependent censoring in a clinical trial.12 We hypothesised that the 
observed positive association between the I allele and AD is due to early 
mortality of the carriers of the D allele from CVD, and correction for that 
co-morbidity bias would diminish that association. We tested this hypothesis 
using data from the Rotterdam Study.
Materials and methods
Study population
This study is embedded in the Rotterdam Study, an ongoing population 
based follow up study. The study is designed to investigate the determinants 
of chronic diseases in the elderly and has been described in more detail 
elsewhere.13 In brief, baseline data were collected between March 1990 and 
July 1993 from 7983 subjects, aged 55 years or older, living in Ommoord, 
a suburb of Rotterdam, The Netherlands.13 The study was approved by the 
Medical Ethics Committee of Erasmus University, and written informed 
110
C
ha
pt
er
 4
.3
  A
C
E
  a
nd
 c
o-
m
or
bi
di
ty
: t
he
 R
ot
te
rd
am
 S
tu
dy
consent was obtained from all participants. The participants were  
interviewed at home by a trained research assistant using computerised 
questionnaires, and subsequently visited the study centre. 
At baseline, the height and weight of the participants were measured 
and body mass index (kg/m2) was computed. An electrocardiogram was 
recorded and two blood pressure measurements were taken, with a random- 
zero sphygmomanometer after a minimum of five minutes rest with the 
participant in a sitting position, and averaged. Total plasma cholesterol and 
high density lipoprotein cholesterol levels were assessed by an automated 
enzymatic procedure using a non-fasting blood sample. Diabetes mellitus 
was defined as the use of glucose-lowering medication and/or a non-fasting  
plasma glucose level ≥ 11.1 mmol/L according to Report of the Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus.14 
Smoking status was defined as current smoker and non-/former smoker, in 
accordance with the interview at baseline. 
Carotid, aortic, and lower-extremity atherosclerosis were assessed. The 
common carotid artery, carotid bifurcation, and internal carotid artery were 
visualised over a length as large as possible by use of ultrasound and  
examined in both the left and right sides for the presence of plaques. A 
plaque score was computed, ranging from 0 to 6 (the maximum number 
of sites). Common carotid intima media thickness (IMT) was determined 
as the average of the IMT of the near- and far-wall measurements over a 
length of 1 cm in the right and left side arteries. Aortic atherosclerosis was 
diagnosed by radiographic detection of calcified deposits in the abdominal 
aorta on a lateral abdominal X-ray. Ankle-arm index was computed as the 
ratio of the systolic blood pressure at the ankle to the systolic blood  
pressure at the right arm. For these analyses, we used the lowest value of 
this measurement in both legs. 
Laboratory assessments 
Blood samples were drawn, and serum and plasma were stored at –80 °C. 
DNA was isolated from blood using a standard procedure (the salting 
out method)15 and the II, ID, and DD genotypes were detected using the 
polymerase chain reaction technique according to the method of  
Lindpaintner et al 16 with some modifications. Details of the genotyping 
method are previously published.17 
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Follow up procedures
Follow up examinations took place in 1993-1994 (first follow up) and in 
1997-1999 (second follow up). Subjects are continuously monitored for 
clinical events through automated linkage of the study database of the 
Rotterdam Study with files from the general practitioners. When an event 
or death has been reported, additional information is obtained from the 
general practitioner and hospital discharge records. All possible coronary 
heart disease (CHD) events (myocardial infarctions and cardiac deaths) and 
strokes are reviewed by physicians and diagnoses are reached during  
consensus meetings. CHD and stroke were classified according to the  
International Classification of Diseases, 10th version (ICD-10).18  
Cardiovascular death was defined as myocardial infarction (I21), ischaemic 
heart disease (I20, I22-I25), sudden death (I46, R96), and death due to 
congestive heart failure (I50). Strokes were defined as ICD codes I60-I64. 
The procedures for the baseline and follow up examinations for  
Alzheimer’s disease diagnoses have been described in detail elsewhere.19 
The Mini-Mental State Examination20 and the cognitive questions from 
the Geriatric Mental State Schedule21 were administered during the home 
interview. Participants in whom dementia was suspected were examined by 
a neurologist and tested by a neuropsychologist, and, if possible, underwent 
brain nuclear magnetic resonance imaging. In addition, participants were 
continuously monitored for development of Alzheimer’s disease through 
linkage between the general practitioners’ medical record system and 
the Rotterdam Study database; this made it possible to obtain follow up 
diagnoses for more than 99% of the cohort. The diagnosis of Alzheimer’s 
disease was based on criteria from the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s disease and 
Related Disorders Association.22 
Data description
In this study we included subjects who screened negative for Alzheimer’s 
disease at baseline. We limited our sample to participants who were 80 
years old or younger at baseline. This selection was in line with our  
hypothesis that the present association is influenced by cardiovascular  
mortality related to the D allele, because the association between the D  
allele and CVD mortality is mainly present among younger age groups.23 
There was, generally, less than 5% missing data for the determinants 
of CVD in this sample. Yet, for some variables like alcohol consumption, 
ankle-arm index, carotid IMT, and plaque scores, there were between 10% 
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and 18% missing values. The missing data were imputed by a multiple  
imputation technique,24 using Multivariate Imputation by Chained  
Equations (MICE) software library written for S-PLUS. Five complete data 
sets were generated (n = 5712) and each analysis was the pooled result of 
the analyses done on each of those five data sets. 
Method of adjustment for competing risks
We defined disease D
C
 (co-morbidity disease) to represent fatal CVD, and 
D
I
 (disease of interest) to represent Alzheimer’s disease in our study. We 
used the inverse probability of censoring weighted analyses method to  
adjust for dependent censoring.12 We assumed that we have data on a  
sufficient number of covariates at baseline so that, conditional on these 
covariates, censoring due to death from D
C
 is independent of the risk of D
I
. 
We then specified a Cox proportional hazards model including all covariates 
for the probability of death from D
C
. The cumulative hazard function was 
calculated for each subject i as:
   (1)
where X
ij
 is the specific determinant j of D
C
 for subject i and β
j
 is the  
coefficient of the determinant j. 
For each subject who did not suffer death from disease D
C
 during follow 
up, we used the results of model (1) to estimate the probability of being 
free from fatal disease D
C
 through the end of their observation period.
(2)
This probability was used to compute a weight for each subject i, that is 
uncensored by fatal disease D
C
. This weight was the inverse of the survival 
probability:
         
        (3)
 
Finally, a weighted Cox proportional hazards model was fitted on disease D
I
: 
       (4)
where Z
ij
 is the specific determinant j of disease D
I
 for subject i. 
An intuitive explanation for these weights is given here. For a person 
with a cumulative probability of 25 percent of being free from death from 
disease D
C
 through the end of follow up, on average, there would have been 
three other persons who were censored by death from disease D
C
 before 
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the end of follow up, but who would have had a similar set of covariates 
and risk of disease D
I
 had censoring been prevented. We therefore assigned 
this person a weight of four in the final regression analysis on disease D
I
. 
These weights are computed in S-PLUS, which allows sampling weights to 
be used. The standard errors of the β coefficients of the Cox proportional 
hazards model are estimated by statistical methods available in S-PLUS that 
are robust against introducing weights.25 
The weighed analysis was performed in each of the five imputed data 
sets. The final result was the pooled estimate of the five analyses according 
to standard multiple imputation methodology.26 Suppose that β
i
 is the  
coefficient of interest (e.g. of the II or the ID genotypes) obtained from 
data set i (i = 1,2,…,M). The pooled estimate is the average of the individual 
estimates:
 
 
 
For the pooled variance, one must first calculate the within-imputation 
variance:
 
 
 
and the between-imputation variance:
 
 
 
The total variance will be:
 
 
 
which, in our study with five imputations, is computed as:
 
 
Results
Demographic characteristics of the participants are presented in Table 1 
for men and women separately. Women were older than men with a mean 
difference less than 0.5 year. Men had a higher risk profile than women 
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considering most of the CVD risk factors (Table 1). There was no  
difference in the D allele frequency between the two genders and the  
distribution of the genotype and allele frequencies were in Hardy-Weinberg 
equilibrium in both genders (p = 0.59 in men and p = 0.62 in women). 
During follow up, 212 fatal cases of CVD (CHD and stroke) and 51 
possible and probable cases of Alzheimer’s disease were recorded in men. 
Among women 168 fatal CVD and 89 AD cases were observed. All  
subjects who died from CVD, but were already screened positive for AD 
were considered as Alzheimer’s disease patients (n = 16 in men and 9 in 
women). Those who died from CVD without previously being screened 
positive for AD were considered as CVD cases (n = 196 and 159 in men 
and women, respectively).
Table 2 shows the results from the Cox proportional hazards regression  
for fatal CVD in univariable and multivariable models in men. In the  
Table 1. Demographic characteristics of the study population
Men (n = 2431) Women (n = 3281)
Age (years) 66.44 ± 6.52 66.83 ± 6.83*
Body mass index (kg/m2) 25.78 ± 2.92 26.71 ± 4.11*
Alcohol consumption (%) 87.67 74.52*
Total cholesterol (mmol/L) 6.37 ± 1.12 6.90 ± 1.18*
HDL cholesterol (mmol/L) 1.21 ± 0.31 1.45 ± 0.37*
Systolic BP (mmHg) 138.31 ± 21.60 137.90 ± 21.86
Diastolic BP (mmHg) 74.90 ± 11.41 73.40 ± 10.99*
Diabetes mellitus (%) 9.67 8.57
Prevalence MI (%)† 17.46 7.12*
Family history of MI (%) 16.91 18.84
Ankle-arm index 1.10 ± 0.21 1.07 ± 0.19*
Common carotid IMT (mm×10–1) 8.19 ± 1.56 7.56 ± 1.41*
Number of carotid plaques ≥ 3 (%) 26.90 15.60*
Aortic calcification (%) 58.20 54.86*
Current smoking (%) 29.23 20.42*
ACE D allele (%) 52.41 53.15
Continuous values are mean ± standard deviation. 
ACE: angiotensin converting enzyme gene; BP: blood pressure; HDL: high density lipoprotein; 
IMT: intima media thickness; MI: myocardial infarction. 
* p < 0.05 compared with men. 
† Myocardial infarction, verified by cardiologist, general practitioner or electrocardiogram. 
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univariable model, all the estimates were adjusted for age. All four  
measurements of atherosclerosis (ankle-arm index, aortic calcification,  
carotid IMT, and plaques) showed significant association with CVD  
mortality. Based on our previous findings on association between the ACE 
I/D polymorphism and cardiovascular mortality in the Rotterdam Study,23 
we also included an interaction between the D allele and smoking status in 
the model. No significant association was observed between the D allele or 
its interaction with smoking and mortality from CVD in men. 
Results of similar analyses in women are presented in Table 3. In general, 
cardiovascular risk factors showed stronger association with CVD mortality 
in women than in men. There was a significant interaction between the D 
allele and smoking in both the univariable and multivariable models. The 
multivariable models were used to compute weights using equations (2) 
Table 2. Cox proportional hazards model for fatal cardiovascular diseases in men
Variable Univariable beta* (95% CI) Multivariable beta (95% CI)
Age (years) 0.124 (0.100, 0.148) 0.088 (0.050, 0.125)
Body mass index (kg/m2) –0.030 (–0.077, 0.017) –0.056 (–0.133, 0.021)
Alcohol consumption –0.329 (–0.725, 0.067) –0.673 (–1.189, –0.158)
Total cholesterol (mmol/L) 0.005 (–0.117, 0.127) –0.087 (–0.276, 0.103)
HDL cholesterol (mmol/L) –0.781 (–1.281, –0.281) –0.406 (–1.159, 0.347)
Systolic BP (mmHg) 0.011 (0.005, 0.017) 0.010 (–0.003, 0.023)
Diastolic BP (mmHg) 0.008 (–0.004, 0.020) 0.010 (–0.014, 0.033)
Diabetes mellitus 0.768 (0.429, 1.107) 0.841 (0.342, 1.341)
Prevalence MI 1.266 (0.982, 1.550) 1.240 (0.813, 1.666)
Family history of MI 0.186 (–0.175, 0.547) –0.128 (–0.729, 0.474)
Ankle-arm index –1.318 (–1.886, –0.750) –0.069 (–0.992, 0.853)
Common carotid IMT (mm×10–1) 1.651 (0.853, 2.449) 0.734 (–0.653, 2.120)
Number of carotid plaques 0.206 (0.124, 0.288) 0.057 (–0.075, 0.189)
Aortic calcification 0.411 (0.078, 0.744) 0.305 (–0.160, 0.770)
Current smoking 0.121 (–0.183, 0.425) –0.485 (–1.443, 0.473)
ACE I/D polymorphism† 0.028 (–0.164, 0.220) –0.035 (–0.370, 0.301)
ACE I/D polymorphism × smoking 0.330 (–0.119, 0.779) 0.436 (–0.247, 1.119)
ACE: angiotensin converting enzyme gene; Beta: regression coefficient; BP: blood pressure; 
CI: confidence interval; HDL: high density lipoprotein; I/D: insertion/deletion; 
IMT: intima media thickness; MI: myocardial infarction. 
* All estimates were adjusted for age. 
† Number of the D alleles was used in the model.  
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and (3) for those who did not experience a fatal CVD event during follow 
up, in men and women separately. 
The un-weighted survival analyses showed a prominent increased risk 
of AD among the II carriers compared with the DD carriers in women 
(hazard ratio = 1.71; 95% confidence interval (CI): 0.97, 3.01) (Table 4). 
Although separate analyses in men also showed an increased risk of AD 
related to the I allele, the estimates were far from statistical significance 
(hazard ratio for II carriers = 1.13; 95% CI: 0.49, 2.60). In the weighted 
analyses, hazard ratios did not materially change among women, and  
declined somewhat in men compared with the un-weighted analyses  
(Table 4). 
Table 3.  Cox proportional hazards model for fatal cardiovascular diseases in 
women
Variable Univariable beta* (95% CI) Multivariable beta (95% CI)
Age (years) 0.140 (0.113, 0.167) 0.098 (0.052, 0.144)
Body mass index (kg/m2) 0.004 (–0.033, 0.041) 0.003 (–0.055, 0.061)
Alcohol consumption –0.444 (–0.803, –0.085) –0.442 (–0.926, 0.042)
Total cholesterol (mmol/L) 0.026 (–0.101, 0.153) –0.066 (–0.260, 0.128)
HDL cholesterol (mmol/L) –0.345 (–0.782, 0.092) –0.167 (–0.849, 0.516)
Systolic BP (mmHg) 0.017 (0.009, 0.025) 0.002 (–0.012, 0.017)
Diastolic BP (mmHg) 0.026 (0.012, 0.040) 0.028 (0.003, 0.054)
Diabetes mellitus 0.863 (0.493, 1.233) 0.482 (–0.163, 1.128)
Prevalence MI 1.052 (0.660, 1.444) 0.732 (0.103, 1.362)
Family history of MI 0.112 (–0.274, 0.498) –0.330 (–0.934, 0.275)
Ankle-arm index –2.394 (–2.960, –1.828) –1.712 (–2.696, –0.729)
Common carotid IMT (mm×10–1) 3.217 (2.351, 4.083) 2.602 (1.404, 3.800)
Number of carotid plaques 0.309 (0.209, 0.409) 0.195 (0.039, 0.350)
Aortic calcification 0.569 (0.142, 0.996) –0.157 (–0.758, 0.445)
Current smoking 0.816 (0.461, 1.171) –0.921 (–2.115, 0.272)
ACE I/D polymorphism† –0.092 (–0.312, 0.128) –0.439 (–0.823, –0.056)
ACE I/D polymorphism × smoking 0.660 (0.152, 1.168) 1.457 (0.618, 2.295)
ACE: angiotensin converting enzyme gene; Beta: regression coefficient; BP: blood pressure; 
CI: confidence interval; HDL: high density lipoprotein; I/D: insertion/deletion; 
IMT: intima media thickness; MI: myocardial infarction. 
* All estimates were adjusted for age. 
† Number of the D alleles was used in the model.  
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Discussion
In this study, we examined the effect of co-morbidity by CVD on the  
association between the angiotensin converting enzyme gene polymorphism 
and Alzheimer’s disease. We used a methodology, previously used in a  
clinical trial, for the first time in a large-scale population based cohort 
study. The results did not show major changes between the standard  
(un-weighted) and corrected (weighted) models, indicating that the  
increased risk of AD associated with the I allele is not due to selective  
cardiovascular mortality related to the D allele. 
When dealing with competing risks in which one of the diseases is 
highly fatal, the effects of determinants on the other disease could be biased 
due to the co-morbidity of these diseases. This, in turn, means that those 
who died from one disease may have been at a higher risk of developing 
the other disease than those who survived. Robins12,27 showed that, having 
available data on all time-dependent prognostic factors that predict censoring, 
one can correct for the dependent censoring by using the inverse probability  
of censoring weighted methodology. In the present study, we used this 
method to adjust for dependent censoring in an observational study on the 
risk of Alzheimer’s disease. The weights were derived from the inverse of the 
probability of death from CVD. We assume that we have data on a  
sufficient number of covariates, such that censoring due to death on CVD 
is independent of the risk of developing Alzheimer’s disease.
We used multiple imputation techniques to generate five imputed data 
sets in order to deal with missing data on the determinants of cardiovascular 
mortality. Multiple imputation has proven to be one of the most efficient 
methods to deal with missing data. Rubin26 showed that the efficiency of an 
estimate based on multiple imputation is dependent on the rate of missing 
information and the number of imputations performed. One can easily 
show that, in practice, between 3 to 10 imputed data sets is sufficient and 
in most situations there is simply little advantage in producing and analysing 
more than a few imputed data sets.26 
Our study failed to show any clear differences between the un-weighted 
and weighted models. Particularly in women, with the highest AD risk 
associated with the II genotype, the risk estimates were the same in the 
un-weighted and weighted analyses. We found a slight decline in the hazard 
ratio estimates in men. Although these changes are in the expected direction 
of a co-morbidity effect, it is important to note that the differences between 
the weighted and un-weighted analyses could occur due to random variation 
introduced by the weighting factor (if the weighting model is imperfect). 
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There could be several explanations for the fact that the co-morbidity 
effect was not observed in our study. Firstly, it is important to use a large 
enough number of covariates as predictors of CVD. In our study, we used 
the conventional cardiovascular risk factors and the majority of them were 
significantly related to the CVD outcome in the Cox regression model. At 
the same time, it is necessary that the same model predicts the incidence of 
AD. The assumption of the inverse probability weighting method is that, 
conditional on covariates, censoring due to CVD is independent of the risk 
of AD. It is likely that our model was not strongly predicting disease in 
either direction and thereby failed to demonstrate the co-morbidity effect. 
Secondly, the effect of co-morbidity might be larger in a younger  
population than the Rotterdam Study. In other words, if dependent  
censoring is present at a young age, it might very well have happened 
before the start of our study, which only includes a cohort aged 55 years or 
older. Finally, the possibility remains that there is no co-morbidity effect in 
the association between the ACE I/D polymorphism, CVD mortality, and 
incidence of AD. 
In summary, we performed the inverse probability of censoring weighted 
analyses method for the first time in a population based cohort study. Our 
results did not provide an evidence for a co-morbidity effect introduced by 
cardiovascular mortality in association with the ACE I/D polymorphism 
and Alzheimer’s disease. The increased risk of AD related to the II genotype 
appears not to be due to excess of cardiovascular mortality among the DD 
carriers. 
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General discussion
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Introduction
Although many developing countries are still fighting against infectious 
diseases and malnutrition among children, most western countries are 
moving toward older populations. In the 21st century, diseases of the elderly 
are more frequently showing their faces, and, among them, atherosclerosis 
is a key feature. It is the main cause of myocardial infarction, stroke, and 
several other organ damaging conditions, such as kidney failure. About half 
of the mortality in the western world and many Asian countries is caused 
by atherosclerotic diseases.1 
In the late 15th century, Leonardo da Vinci (1452-1519) described the 
atherosclerosis condition for the first time. In his book, The Anatomy of the 
Old Man, he stated, “vessels in the elderly, through the thickening of the 
tunics, restrict the transit of the blood”. It was not, however, until the mid 
20th century that epidemiologists tried to reveal its complexity by determining  
the risk factors involved in this condition. By now, numerous factors have 
been related to atherosclerosis;2 some of them are purely environmental, 
such as smoking, lack of exercise, and high-fat diet. Other risk factors for 
atherosclerosis are (partly) of genetic origin, which means they are passed 
from parents to their children. Hypertension, hyperlipidaemia, and  
diabetes are among these factors.2 As in other complex disorders, interactions 
between environmental and genetic risk factors also play an important role 
in the formation and progression of atherosclerosis. 
Known risk factors of atherosclerosis only explain between 20% to 
40% of the total variance for this trait.3,4 This means that a large portion 
of atherosclerosis risk factors is still unknown. It is expected that these 
unknown factors consist of environmental and genetic components. Our 
knowledge of the key genes involved in the development of atherosclerosis 
is still limited despite the large number of studies conducted to date.2 The 
contribution of genetic factors (heritability) can be estimated by measuring 
atherosclerosis in people who are related to each other. Based on the work 
performed in this thesis (chapter 2) and the work of other researchers,5 we 
conclude that around 30% to 40% of the unknown portion of atherosclerosis 
risk factors is genetically determined. One important fact, however, is that 
this proportion could vary between different populations. Considering the 
complex interaction between genetic and environmental factors, it is  
expected that a certain genetic factor may not become involved in the process 
of atherosclerosis unless another gene or environmental factor is present. 
For instance, genes involved in salt sensitivity will not express in a population  
with low salt intake. This implies that the contribution of genes to a trait 
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may differ between populations. 
Another characteristic of the arteries, namely arterial stiffness, is also an 
important factor related to cardiovascular diseases.6,7 Atherosclerosis and 
arterial stiffness have been found to be correlated,8 although the interrelation 
of the two traits at different stages of atherosclerosis is not completely 
known. Studies on the genetic factors of arterial stiffness are limited in 
number. A few candidate genes have been identified so far, most of them 
focused on genetic polymorphisms in the renin angiotensin system.9-13 
To our knowledge, there has been no published report on the heritability 
of this trait. In chapter 2, we studied the heritability of arterial stiffness, 
measured by carotid-femoral pulse wave velocity (PWV), in a genetically 
isolated population. We found a heritability estimate of about 35% that is 
comparable to the heritability of carotid intima media thickness (IMT) in 
the same population. 
This thesis also includes some work on one of the genetic risk factors 
contributing to the genetic complexity of atherosclerosis. We focused on the 
angiotensin converting enzyme (ACE), which is a key component in the 
renin angiotensin system and some other physiological systems, by using one 
of the variations in its gene, the insertion/deletion polymorphism (I/D). 
The renin angiotensin system
Renin angiotensin system is a hormonal system that helps to regulate  
long-term blood pressure and blood volume in the body. Renin is released 
by the juxtaglomerular cells in the kidneys under conditions of salt or  
volume loss or sympathetic activation. It cleaves the inactive peptide  
angiotensinogen (synthesised in the liver), producing angiotensin I, which 
in turn is converted to angiotensin II by the act of angiotensin converting 
enzyme. 
Angiotensin II has a variety of effects on the body. In the kidneys, it 
constricts glomerular arterioles, which decreases the glomerular filtration 
rate and, in turn, raises systemic arterial blood pressure. It also acts on the 
adrenal cortex, causing the release of aldosterone, which acts on the tubules 
in the kidneys, allowing them to reabsorb more sodium and water from 
the urine.14 These effects directly act to increase the amount of fluid in the 
blood, making up for a loss in volume, and to increase blood pressure.
In addition, angiotensin II is a potent vasoconstrictor. It also mediates 
cell growth and the proliferation of vascular smooth muscle cells,  
cardiomyocytes and coronary endothelial cells by stimulating various  
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cytokines and growth factors, such as insulin-like growth factor-I and 
platelet derived growth factor.15 Furthermore, angiotensin II may induce 
endothelial dysfunction by reducing nitric oxide biovailability.16 These 
findings emphasise the importance of angiotensin II in cardiovascular 
pathophysiology and stimulate exploration of the role of the genetic poly-
morphisms present in the renin angiotensin system in the search for genetic 
factors involved in atherosclerosis and other cardiovascular outcomes. 
Angiotensin converting enzyme  
insertion/deletion polymorphism
ACE is a zinc metallopeptidase widely distributed on the surface of  
endothelial and epithelial cells. It converts angiotensin I to angiotensin 
II, the main active product of the renin angiotensin system.17 At the same 
time, ACE also plays an important role in the kinin kallikrein system by 
inactivating bradykinin, which is a strong vasodilator. In the central  
nervous system (CNS), ACE is also expressed, with the primary function of 
degrading some of the neurotransmitters involved in the transmission of 
pain, the regulation of emotions, and the alteration of inflammatory and 
immune responses.18,19 
The human ACE gene is located on chromosome 17q23 and includes 26 
exons. In 1990, Rigat and co-workers published an important report that 
provided the impetus to further study polymorphisms on this gene.20 They 
found a polymorphism involving the presence (insertion, I) or absence  
(deletion, D) of a 287 bp sequence of DNA in intron 16 of the gene.  
Interestingly, the mean ACE activity level in DD genotype individuals was 
about twice that found in II genotype individuals.20 Subjects with ID  
genotype had intermediate levels indicating co-dominancy; that is, the  
effects of both alleles are detectable in heterozygotes. It was hypothesised 
that the higher ACE levels could result in increased angiotensin I to  
angiotensin II conversion. Considering the importance of angiotensin II in 
cardiovascular pathophysiology, it is not surprising that many studies have 
tried to find an association between the ACE I/D polymorphism and  
different cardiovascular diseases. 
In this thesis, we investigated the relation between this polymorphism 
and atherosclerosis. As the first step, we made an effort to put together the 
findings from previously published studies in a meta-analysis (chapter 3.1) 
and we found a positive association between the D allele and carotid IMT 
in populations who are at high risk of atherosclerosis. This suggests the 
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presence of some interaction between the D allele and other atherosclerosis 
risk factors. Based on this finding, we looked for other determinants of 
ACE plasma level using data from the Rotterdam Study, and we found that 
smoking increases plasma ACE levels (chapter 3.2). Therefore, we  
hypothesised that the D allele and smoking might interact to cause  
atherosclerosis. We did, indeed, find this interaction using IMT as a  
measurement of atherosclerosis (chapter 3.2). Further support for this  
interaction was provided when we studied the I/D polymorphism in  
relation to cardiovascular mortality and we found a higher risk of mortality 
related to the D allele only among smokers. This association was mainly 
present in younger subjects in our population (chapter 4.1). We also  
studied the relation between this polymorphism and arterial stiffness using 
two different measurements, carotid-femoral PWV and carotid distensibility. 
No relation between the polymorphism and PWV was found, while the 
D allele was related to a higher stiffness in the carotid artery. In stratified 
analyses, the association was stronger in subjects younger than 70 years in 
this population of individuals who were 55 years or older (chapter 3.3). 
Other polymorphisms in the ACE gene
The I/D is not the only polymorphism in the ACE gene. The National 
Centre of Biological Information (NCBI) lists more than 160  
polymorphisms in this gene, most of which are single nucleotide  
polymorphisms (SNPs). The I/D polymorphism is located in a non-coding 
region of the ACE gene, meaning that presence or absence of the alu repeat 
is not likely to modify the structure, and thus, the function and activity of 
the synthesised protein. Many studies investigated the association between 
the other variants in this gene and plasma ACE levels, and some researchers  
could narrow down the region where the functional polymorphism is likely 
to be located.21,22 However, there is no final agreement as to which variant 
is responsible for the changes in ACE levels. Although one would like to 
know the functional polymorphism in this gene, the I/D polymorphism is 
still useful in association studies. This issue will be explained in more detail 
in the section on methodological aspects in this chapter. 
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I/D polymorphism and other complex diseases
Besides relationship between the ACE I/D and atherosclerosis related 
outcomes, we also examined its relationship with total mortality (chapter 
4.2). We observed that there is a higher risk of mortality related to the DD 
genotype, especially at younger ages among smokers. Although this effect 
modification was similar to our finding on the ACE I/D and cardiovascular  
mortality in chapter 4.1, unpublished data from the Rotterdam Study 
suggest that this finding cannot singularly be ascribed to the relationship 
between the polymorphism and cardiovascular mortality. In fact, this  
observation might be explained by other causes of death, which is supported 
by a large body of literature on wide range of ACE actions in multiple 
physiological systems. 
In the renin angiotensin system, angiotensin II production is mediated 
by ACE. Experimental studies demonstrate that angiotensin II promotes 
angiogenesis, an important determinant in the growth and spread of many 
human cancers. Angiotensin II induces vascular endothelial growth factor,  
which plays a pivotal role in tumour angiogenesis and correlates with  
aggressive behaviour and a poor prognosis.23,24 In addition, angiotensin II 
stimulates the production of growth factors such as transforming growth 
factor-I, platelet-derived growth factor, and basic fibroblast growth factor.25 
Given those observations, many researchers investigated the relationship 
between the ACE I/D polymorphism and several types of cancer, such as 
prostate, endometrial, and breast cancer.26-28 
Besides its role in the renin angiotensin system, ACE also plays an  
important role in the kinin kallikrein system by degrading bradykinin, 
a powerful vasodilator. In skeletal muscle tissue, a local kinin kallikrein 
system exists that liberates kinins and express bradykinin B-2 receptors.29 
Bradykinin infused at physiological doses produces an endothelial  
dependent increase in muscle blood flow and glucose extraction rates.30  
Recent studies have suggested that the I allele of the ACE I/D  
polymorphism might be associated with some aspects of endurance  
performance, being found with increased frequency in elite distance  
runners,31 rowers32 and mountaineers.33 A recent case-control study also 
suggested that DD carriers are eight times more likely to develop chronic 
fatigue syndrome than those with the II genotype,34 suggesting a lower 
metabolic efficiency in DD carriers. 
There are still other functions associated with ACE. In the CNS,  
ACE is responsible for degeneration of a family of neurotransmitters known 
as neurokinins, which appear to play a key role in the regulation of  
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emotions.18,19 Although the role of ACE in degenerating these  
neurotransmitters is not always replicated,35 it has triggered studies on the 
ACE I/D polymorphism and neurological diseases such as depression,36-38 
other affective disorders,39 and Parkinson disease.40 The role of ACE in the 
CNS, however, is not limited to these neurotransmitters. It has been  
demonstrated that ACE degrades amyloid beta peptide in vitro,41 one of the 
primary adverse biological agents implicated in Alzheimer’s disease (AD) 
pathogenesis.42,43 Thus, if present in sufficient levels in vivo, ACE may  
preclude or lessen the formation of senile plaques, which are  
neuropathological hallmarks of AD. A recent large-scale study involving 
multiple markers spanning ACE, in conjunction with a meta-analysis of 
previously published data on the I/D polymorphism, supports the hypothesis  
that the I allele contributes to AD.44 
The ACE I/D has also studied with respect to many other diseases, with 
various theories on the possible pathways. To mention them briefly, the 
role of the ACE polymorphism has been examined in relation to conditions 
such as insulin resistance,45-47 asthma, 48,49 pneumonia,50 sarcoidosis,51 and 
systemic lupus erythematosus.52,53
Methodological aspects
Causality and linkage disequilibrium
Association studies, by their nature, may show a statistical correlation 
between a given polymorphism and a certain phenotype (a change in the 
level of an enzyme, risk of developing a disease, etc.). From a pathogenetic 
point of view, however, this does not prove a causal relationship. If a non-
functional allele under study and the allele that cause the phenotype are not 
physically close to each other, they are in “linkage equilibrium” and  
inherited independently according to Mendelian laws. If, however, the  
distance between these DNA segments is close enough, it results in  
“linkage disequilibrium”, a situation in which the allele under study does 
appear together with the phenotype more often than would be expected  
according to the allelic distribution in the population. In other words, 
the non-functional polymorphism may act as a marker for the mutation 
responsible for the phenotype. 
In Caucasian populations, most of the polymorphisms on the ACE gene 
are in close linkage disequilibrium with the I/D polymorphism. The fact 
that the I/D may not be the functional polymorphism could only dilute the 
effect and increase the chance of false negative results in association studies. 
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Despite this, the positive association between the ACE I/D polymorphism 
and atherosclerosis (or other outcomes) could still be an important finding 
even if this polymorphism is only a marker flagging the functional mutation. 
Cause versus consequence
An important aspect of studying the relation between candidate genes and 
(patho)physiological conditions is that the temporal relationship is mostly 
unharmed. Environmental or physiological factors may have changed due 
to a disease condition and, in most epidemiological designs, such as cross-
sectional or case-control studies, it is extremely difficult to distinguish 
between the causes and consequences of the disease. A cohort or a nested 
case-control study design, of course, gives us the opportunity to measure 
the risk factors before the outcome has occurred. With regard to complex 
diseases that develop in an elderly population, however, the subclinical 
processes of the disease generally start long before the disease becomes 
manifest. In this situation, defining a temporal relationship between the 
risk factor and the disease becomes problematic. The genetic make-up of a 
person, however, is unique throughout his life. In other words, genetic risk 
factors are not altered by any disease status, which is one of the advantages 
of genetic association studies. The only point of concern is that selection 
may have occurred based on genotypes in a study on prevalent patients. 
This problem can be overcome by using only the incident cases in a study. 
Co-morbidity effect 
A possible source of bias, which also occurs in studies using incident cases, 
is the presence of a co-morbidity effect. In an association study on a given 
risk factor and a certain disease, the presence of selective censoring could be 
a cause of bias. The association between ACE and multiple diseases on the 
one hand, and the common pathophysiological pathways of these diseases 
on the other hand, provided us with the opportunity to study the ACE I/D 
polymorphism in relation to Alzheimer’s disease as an example of such a 
situation. The evidence of an association between atherosclerosis and AD44 
and the possible relationship between the D allele and cardiovascular  
diseases,54 lead to the hypothesis that the observed association between the 
ACE I allele and AD could be due to selective censoring of carriers of the D 
allele due to cardiovascular mortality. In chapter 4.3, we used the method 
of weighted analyses using the inverse probability of censoring to evaluate 
this problem. We compared the standard (un-weighted) and corrected  
(weighted) risk estimates using the inverse probability of censoring analyses 
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and we observed no differences in estimated risks, indicating that the  
relation between the I allele and AD is not likely to be due to a selective 
censoring of the cases with cardiovascular mortality among the DD carriers. 
Genetic research in isolated populations
Due to the complexity of the genetic basis of atherosclerosis, any attempt 
to eliminate part of that complexity may eventually lead to more feasible 
approaches toward understanding this disorder. One way to accomplish 
this is to use genetically isolated populations, an idea that has emerged over 
the last few years. The general assumption is that an isolated population is 
descended from a limited number of founders and, therefore, genetic  
heterogeneity in a sample from such a population is reduced compared 
with a sample from the general population. In this thesis, we presented the 
first report on atherosclerosis in the Erasmus Rucphen Family (ERF) study, 
an ongoing study in an isolated population in the southwest of The  
Netherlands. Until now, we only studied the heritability estimates of  
atherosclerosis and arterial stiffness. The purpose of the ERF study is to 
search for new genetic factors in these traits by the use of extensive genealogy  
data, which allow us to conduct family based studies. Candidate gene 
studies as well as a genome wide screen will be performed in this design. In 
addition, when a new genetic risk factor is found in this isolated population, 
we can determine the contribution of the gene to the trait in the general 
population by using the design of the Rotterdam Study. 
Multiple testing
Recently, automation of laboratory techniques has made it possible to 
genotype large number of SNPs from all over the genome very quickly and 
accurately. Using the information from these polymorphisms in the whole 
genome and testing the association between each of them and a selected 
outcome is a very tempting idea. By performing large number of statistical 
tests with no other a priori hypothesis than that a polymorphism is involved, 
the possibility increases that the positive findings are simply due to 
chance.55 One method for dealing with this scenario is to correct for multiple  
testing by known statistical methods, such as the Bonferroni correction. A 
point of concern is the chance of false negative findings. Using a Bonferroni 
correction, a larger sample size is needed in order to execute a study with 
sufficient statistical power. An alternative way might be to test the  
significance of associations using conventional statistical significance levels 
and, in a second step, make an attempt to replicate the positive findings in 
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a second population. In this way, we decrease the chance of false negative 
findings at the cost of a higher chance of false positives that will be judged 
in the replication stage. 
Future studies
In this thesis, we observed associations between the D allele and IMT, 
arterial stiffness, cardiovascular mortality, and total mortality. Although a 
lot of work has been done,56,57 it is clear that we are in great need of more 
basic physiological studies that investigate the relation between the ACE 
gene and atherosclerosis, especially with regard to possible interactions. The 
pathophysiological mechanism underlying the interaction between the D 
allele and smoking that has been found in the studies comprising this thesis 
has yet to be evaluated. Experimental studies utilizing animal models may 
show if this interaction is due to an increased level of ACE and an  
alteration in the renin angiotensin system, or whether it works through 
other pathophysiological pathways. Furthermore, the findings of this thesis 
on the relationship between the ACE I/D and atherosclerosis, cardiovascular 
endpoints, or other clinical outcomes need to be replicated. Especially our 
findings on the interaction between the D allele and smoking, which has 
not been reported before, needs to be confirmed in other studies. The only 
way to show if these are real effects or false positive findings is to replicate 
them with a different study sample. In the next step, the role of other 
genetic factors that contribute to the renin angiotensin system or the kinin 
kallikrein system should be studied. Proteins that are involved in a single 
system (or inter-connected systems) are more likely to modify the effects of 
each other. Studying the interactions between the genetic variations  
responsible for changes in the function or level of these proteins is a  
plausible research plan. 
Genetic association studies can be done in a cohort study design in 
a general population (like the Rotterdam Study) as well as in genetically 
isolated populations (like the ERF study). A case-control design might be 
a good alternative if incident cases are used to avoid a possible selection 
bias. Nested case-controls studies, therefore, are preferable. Considering the 
relatively small effect of each polymorphism and the multiple subgroups 
that should be examined for possible interactions, studies with large sample 
sizes are needed in order to have enough power to detect any interaction. 
In addition, it will be very useful to perform a systematic literature review 
(for example by using a meta-analysis), before the start of a new association 
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study. It may provide useful information to build up an accurate a priori 
hypothesis. 
Another important issue when conducting a candidate gene association 
study is to choose the appropriate polymorphisms in the candidate genes. 
Since the completion of the Human Genome Project, a huge amount 
of information on SNPs throughout the genome has become available. 
Although some of those SNPs may show functional properties, it might be 
a haplotype (combination of several SNPs) that indicates the changes of 
the protein in a more precise way. Using only one SNP or an inappropriate 
combination of SNPs will lead to a misclassification of the risk factor and 
increase the chance of false negative findings. 
Besides studies on candidate genes, it is, of course, interesting to know 
more about unknown genetic factors involved in cardiovascular diseases. 
As mentioned earlier, arterial stiffness is a trait that has been related to 
different cardiovascular outcomes but few studies have been performed 
on genetic risk factors for this trait. We made the first step toward a better 
understanding of the genetic basis of this trait by reporting, for the first 
time, the heritability of carotid-femoral PWV in an isolated population. 
This heritability estimate was close to the heritability of IMT. This finding 
supports the search for genetic determinants of arterial stiffness as well as 
for atherosclerosis. 
In recent years, there has also been increasing interest in  
pharmacogenomics.58 Studies aiming to identify genes involved in  
medication response conducted to date have typically followed a population 
based approach.59,60 The lower genetic complexity of an isolated population  
and the availability of extensive genealogical data will provide us with 
unique opportunities to conduct research with a family based approach to 
localise and identify new genes, such as genes involved in patients’ response 
to medication.61 If there are genes involved in a patients’ response to  
medications, these genes will segregate in families. As a consequence,  
non-response to treatment will cluster in families and we should be able 
to detect the genes involved using classical family based approaches such 
as linkage analysis. A proof of principle of this design will be to find genes 
that are involved in response to antihypertensive treatment in the ERF study. 
Vast amounts of work will be necessary to grasp the whole picture of 
a complex disease such as atherosclerosis. Modern laboratory techniques, 
super computers and new statistical packages are important tools for the 
future that should be used carefully. In lay terms, using these tools is like 
driving a fast car on a highway: a careless driver will harm both himself and 
the others on the road. 
135
ACE  and Atherosclerosis
References
1.   Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature. 1993;362:801-809.
2.   Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
3.   Xiang AH, Azen SP, Buchanan TA, Raffel LJ, Tan S, Cheng LS, Diaz J,  
Toscano E, Quinonnes M, Liu CR, Liu CH, Castellani LW, Hsueh WA,  
Rotter JI, Hodis HN. Heritability of subclinical atherosclerosis in Latino 
families ascertained through a hypertensive parent. Arterioscler Thromb Vasc 
Biol. 2002;22:843-848.
4.   Lange LA, Bowden DW, Langefeld CD, Wagenknecht LE, Carr JJ, Rich SS, 
Riley WA, Freedman BI. Heritability of carotid artery intima-medial  
thickness in type 2 diabetes. Stroke. 2002;33:1876-1881.
5.   Zannad F, Benetos A. Genetics of intima-media thickness. Curr Opin Lipidol. 
2003;14:191-200.
6.   Lehmann ED, Hopkins KD, Jones RL, Rudd AG, Gosling RG. Aortic  
distensibility in patients with cerebrovascular disease. Clin Sci (Lond). 
1995;89:247-253.
7.   Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetieere P, 
Guize L. Pulse pressure: a predictor of long-term cardiovascular mortality in a 
French male population. Hypertension. 1997;30:1410-1415.
8.   van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman 
RS, Hoeks AP, van der Kuip DA, Hofman A, Witteman JC. Association 
between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke. 
2001;32:454-460.
9.   Gardier S, Vincent M, Lantelme P, Rial MO, Bricca G, Milon H. A1166C 
polymorphism of angiotensin II type 1 receptor, blood pressure and arterial 
stiffness in hypertension. J Hypertens. 2004;22:2135-2142.
10.   Bozec E, Lacolley P, Bergaya S, Boutouyrie P, Meneton P, Herisse-Legrand 
M, Boulanger CM, Alhenc-Gelas F, Kim HS, Laurent S, Dabire H. Arterial 
stiffness and angiotensinogen gene in hypertensive patients and mutant mice. 
J Hypertens. 2004;22:1299-1307.
11.   Mattace-Raso FU, van der Cammen TJ, Sayed-Tabatabaei FA, van Popele 
NM, Asmar R, Schalekamp MA, Hofman A, van Duijn CM, Witteman JC. 
Angiotensin-converting enzyme gene polymorphism and common carotid 
stiffness. The Rotterdam study. Atherosclerosis. 2004;174:121-126.
12.   Taniwaki H, Kawagishi T, Emoto M, Shoji T, Hosoi M, Kogawa K, 
Nishizawa Y, Morii H. Association of ACE gene polymorphism with arterial 
stiffness in patients with type 2 diabetes. Diabetes Care. 1999;22:1858-1864.
13.   Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, Larosa E, 
Guize L, Safar M, Soubrier F, Cambien F. Influence of angiotensin- 
converting enzyme and angiotensin II type 1 receptor gene polymorphisms 
on aortic stiffness in normotensive and hypertensive patients. Circulation. 
1996;94:698-703.
14.   Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and 
136
C
ha
pt
er
 5
  G
en
er
al
 d
is
cu
ss
io
n
the kidney: effects on kidney disease. Am J Med. 2004;116:263-272.
15.   Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms 
in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest. 
2001;31:476-488.
16.   Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, 
Harrison DG. Angiotensin II-mediated hypertension in the rat increases 
vascular superoxide production via membrane NADH/NADPH oxidase 
activation. Contribution to alterations of vasomotor tone. J Clin Invest. 
1996;97:1916-1923.
17.   Erdos EG, Skidgel RA. The angiotensin I-converting enzyme. Lab Invest. 
1987;56:345-348.
18.   Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic 
specificities of the two active sites of angiotensin I-converting enzyme  
(kininase II). Studies with bradykinin and other natural peptides. J Biol 
Chem. 1993;268:9496-9503.
19.   Yokosawa H, Endo S, Ogura Y, Ishii S. A new feature of angiotensin-converting 
enzyme in the brain: hydrolysis of substance P. Biochem Biophys Res Commun. 
1983;116:735-742.
20.   Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An 
insertion/deletion polymorphism in the angiotensin I-converting enzyme 
gene accounting for half the variance of serum enzyme levels. J Clin Invest. 
1990;86:1343-1346.
21.   Zhu X, McKenzie CA, Forrester T, Nickerson DA, Broeckel U, Schunkert H, 
Doering A, Jacob HJ, Cooper RS, Rieder MJ. Localization of a small  
genomic region associated with elevated ACE. Am J Hum Genet. 
2000;67:1144-1153.
22.   Keavney B, McKenzie CA, Connell JM, Julier C, Ratcliffe PJ, Sobel E,  
Lathrop M, Farrall M. Measured haplotype analysis of the angiotensin-I  
converting enzyme gene. Hum Mol Genet. 1998;7:1745-1751.
23.   Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect 
in vivo involves vascular endothelial growth factor- and inflammation-related 
pathways. Lab Invest. 2002;82:747-756.
24.   Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, Imazu H, 
Fukui H. Suppression of the renin-angiotensin system attenuates vascular 
endothelial growth factor-mediated tumor development and angiogenesis in 
murine hepatocellular carcinoma cells. Int J Oncol. 2002;20:1227-1231.
25.   Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine 
growth factors modulate vascular smooth muscle cell growth response to 
angiotensin II. J Clin Invest. 1993;91:2268-2274.
26.   Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, 
Lopes C. Linkage of angiotensin I-converting enzyme gene insertion/deletion  
polymorphism to the progression of human prostate cancer. J Pathol. 
2004;202:330-335.
27.   Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R. 
Angiotensin I-converting enzyme gene insertion/deletion polymorphism and 
137
ACE  and Atherosclerosis
endometrial human cancer in normotensive and hypertensive women. Cancer 
Genet Cytogenet. 2004;155:42-46.
28.   Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC.  
Angiotensin I-converting enzyme (ACE) gene polymorphism and breast  
cancer risk among Chinese women in Singapore. Cancer Res. 2003;63:573-578.
29.   Rabito SF, Minshall RD, Nakamura F, Wang LX. Bradykinin B2 receptors on 
skeletal muscle are coupled to inositol 1,4,5-trisphosphate formation.  
Diabetes. 1996;45 Suppl 1:S29-33.
30.   Dietze G, Wicklymayr M, Mayer L. Evidence for a participation of the  
kallikrein-kinin system in the regulation of muscle metabolism during  
hypoxia. Hoppe Seylers Z Physiol Chem. 1977;358:633-638.
31.   Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery 
H. Human angiotensin I-converting enzyme gene and endurance performance. 
J Appl Physiol. 1999;87:1313-1316.
32.   Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, Trent RJ. 
Elite endurance athletes and the ACE I allele, the role of genes in athletic 
performance. Hum Genet. 1998;103:48-50.
33.   Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson P,  
Dollery C, Hayward M, Holliman DE, Jubb M, World M, Thomas EL, 
Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M,  
Talmud PJ, Humphries SE. Human gene for physical performance. Nature. 
1998;393:221-222.
34.   Vladutiu GD, Natelson BH. Association of medically unexplained fatigue 
with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle 
Nerve. 2004;30:38-43.
35.   Lantz I, Thornwall M, Kihlstrom JE, Nyberg F. A comparison of human 
lung, brain, CSF and plasma angiotensin-converting enzyme with regard to 
neuropeptide metabolism. Biochem Int. 1992;26:415-426.
36.   Hong CJ, Wang YC, Tsai SJ. Association study of angiotensin I-converting 
enzyme polymorphism and symptomatology and antidepressant response in 
major depressive disorders. J Neural Transm. 2002;109:1209-1214.
37.   Baghai TC, Schule C, Zill P, Deiml T, Eser D, Zwanzger P, Ella R, Rupprecht 
R, Bondy B. The angiotensin I converting enzyme insertion/deletion  
polymorphism influences therapeutic outcome in major depressed women, 
but not in men. Neurosci Lett. 2004;363:38-42.
38.   Baghai TC, Schule C, Zwanzger P, Minov C, Zill P, Ella R, Eser D, Oezer S, 
Bondy B, Rupprecht R. Hypothalamic-pituitary-adrenocortical axis  
dysregulation in patients with major depression is influenced by the  
insertion/deletion polymorphism in the angiotensin I-converting enzyme 
gene. Neurosci Lett. 2002;328:299-303.
39.   Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An  
insertion/deletion polymorphism in the angiotensin converting enzyme gene 
is associated with both brain substance P contents and affective disorders. Biol 
Psychiatry. 1996;40:1122-1127.
40.   Mellick GD, Buchanan DD, McCann SJ, Davis DR, Le Couteur DG, Chan 
138
C
ha
pt
er
 5
  G
en
er
al
 d
is
cu
ss
io
n
D, Johnson AG. The ACE deletion polymorphism is not associated with 
Parkinson’s disease. Eur Neurol. 1999;41:103-106.
41.   Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme 
degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta  
aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol 
Chem. 2001;276:47863-47868.
42.   Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 
1991;6:487-498.
43.   van Duijn CM, Hendriks L, Cruts M, Hardy JA, Hofman A, van  
Broeckhoven C. Amyloid precursor protein gene mutation in early-onset 
Alzheimer’s disease. Lancet. 1991;337:978.
44.   Kehoe PG. The renin-angiotensin-aldosterone system and Alzheimer’s  
disease? J Renin Angiotensin Aldosterone Syst. 2003;4:80-93.
45.   Panahloo A, Andres C, Mohamed-Ali V, Gould MM, Talmud P, Humphries 
SE, Yudkin JS. The insertion allele of the ACE gene I/D polymorphism. A 
candidate gene for insulin resistance? Circulation. 1995;92:3390-3393.
46.   Chiu KC, McCarthy JE. The insertion allele at the angiotensin I-converting  
enzyme gene locus is associated with insulin resistance. Metabolism. 
1997;46:395-399.
47.   Paolisso G, Tagliamonte MR, De Lucia D, Palmieri F, Manzella D, Rinaldi 
C, Bossone A, Colaizzo D, Margaglione M, Varricchio M. ACE gene poly-
morphism and insulin action in older subjects and healthy centenarians. J Am 
Geriatr Soc. 2001;49:610-614.
48.   Tomita H, Sato S, Matsuda R, Ogisu N, Mori T, Niimi T, Shimizu S. Genetic 
polymorphism of the angiotensin-converting enzyme (ACE) in asthmatic 
patients. Respir Med. 1998;92:1305-1310.
49.   Lee YC, Cheon KT, Lee HB, Kim W, Rhee YK, Kim DS. Gene  
polymorphisms of endothelial nitric oxide synthase and angiotensin- 
converting enzyme in patients with asthma. Allergy. 2000;55:959-963.
50.   Morimoto S, Okaishi K, Onishi M, Katsuya T, Yang J, Okuro M, Sakurai 
S, Onishi T, Ogihara T. Deletion allele of the angiotensin-converting 
enzyme gene as a risk factor for pneumonia in elderly patients. Am J Med. 
2002;112:89-94.
51.   Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J, Jr., 
Iannuzzi MC. Angiotensin-converting enzyme gene polymorphism and risk 
of sarcoidosis. Am J Respir Crit Care Med. 1998;158:1566-1570.
52.   Prkacin I, Novak B, Sertic J, Mrzljak A. Angiotensin-converting enzyme 
gene polymorphism in patients with systemic lupus. Acta Med Croatica. 
2001;55:73-76.
53.   Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, Baird T, 
Hutchings D, Bruner G, Scofield RH, Moser K, Harley JB. Linkage analysis 
of angiotensin-converting enzyme (ACE) insertion/deletion polymorphism 
and systemic lupus erythematosus. Mol Cell Endocrinol. 2001;177:81-85.
54.   Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic 
perspective. Neurobiol Aging. 2000;21:153-160.
139
ACE  and Atherosclerosis
55.   Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta- 
analysis of genetic association studies supports a contribution of common 
variants to susceptibility to common disease. Nat Genet. 2003;33:177-182.
56.   Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR,  
Riegger GA, Schunkert H. Angiotensin-converting enzyme in the  
human heart. Effect of the deletion/insertion polymorphism. Circulation. 
1995;92:1387-1388.
57.   Danser AH, Deinum J, Osterop AP, Admiraal PJ, Schalekamp MA.  
Angiotensin I to angiotensin II conversion in the human forearm and leg.  
Effect of the angiotensin converting enzyme gene insertion/deletion  
polymorphism. J Hypertens. 1999;17:1867-1872.
58.   Terra SG, Johnson JA. Pharmacogenetics, pharmacogenomics, and  
cardiovascular therapeutics: the way forward. Am J Cardiovasc Drugs. 
2002;2:287-296.
59.   Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T  
polymorphism of the G protein beta(3)-subunit and antihypertensive  
response to a thiazide diuretic. Hypertension. 2001;37:739-743.
60.   Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, 
Nystrom F, Lind L, Syvanen AC. A microarray minisequencing system for 
pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics.  
2003;13:7-17.
61.   Halapi E, Stefansson K, Hakonarson H. Population genomics of drug  
response. Am J Pharmacogenomics. 2004;4:73-82.
140
C
ha
pt
er
 5
  G
en
er
al
 d
is
cu
ss
io
n
141
ACE and Atherosclerosis
Summary
142
Su
m
m
ar
y
Summary
Atherosclerosis, a progressive disorder of the large arteries, is the major  
factor in the pathophysiology of cardiovascular diseases. Around half of all 
the deaths in western society is due to these diseases. Knowing the risk  
factors involved in the formation and progress of atherosclerosis will  
eventually lead to a better understanding of this pathophysiological  
condition and, thereby, better ways to prevent or treat it. In the last 50 
years, many epidemiological studies attempted to discover the risk factors 
for atherosclerosis. Many such factors have been discovered; some are purely 
environmental and others have important genetic components. In this 
thesis we worked on the genetic basis of atherosclerosis, mainly by focusing 
on one of the famous genetic polymorphisms, the angiotensin converting 
enzyme (ACE) insertion/deletion (I/D) polymorphism.
Chapter 1 is a general introduction on known aspects of atherosclerosis 
and the different kinds of measurements that have been used in this thesis. 
The concept of genetics in atherosclerosis is discussed and some basic  
information about the ACE I/D polymorphism is given. 
In chapter 2, we present heritability estimates, showing the extent to 
which genetic factors contribute to different measures of arterial wall  
structure and function. We used carotid-femoral pulse wave velocity 
(PWV) as an indicator of arterial stiffness, and carotid intima media  
thickness (IMT) and plaque score as indicators of atherosclerosis. The 
analyses were performed on a sample from a genetically isolated population  
in the southwest of The Netherlands, participants in the Erasmus Rucphen 
Family (ERF) study. ERF is an ongoing study conducted among 2500 
participants from the isolate who belong to a single large pedigree. This 
pedigree was not selected on the basis of any disease status. The results 
presented in chapter 2 are the first report on atherosclerosis from the ERF 
study, using data from 930 participants available at the time of the analyses. 
Heritability estimates of PWV, IMT, and carotid plaques are presented. 
Age and gender adjusted heritability estimates were 0.36 for PWV, 0.41 for 
carotid IMT, and 0.28 for plaque score. After adjustment for appropriate 
risk factors, the heritabilities were 0.26, 0.35, and 0.21 for PWV, IMT and 
plaque score, respectively. All heritability estimates were statistically  
significant. To our knowledge, this is the only report on the heritability 
of PWV, which is quite similar to the heritability estimates of IMT and 
plaque score in our study. These findings suggest that the search for genes 
responsible for arterial stiffness might be as valuable as the search for genes 
involved in atherosclerosis. 
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Chapter 3 consists of studies on the ACE I/D polymorphism and  
atherosclerosis measurements. Previously published studies on the  
relationship between the ACE I/D and carotid IMT measurements have 
been inconsistent. In chapter 3.1, we present a meta-analysis that shows the 
results of the previous studies combined. Based on those results, there is a 
stronger association among the purportedly “high-risk” populations. After 
making that observation, we performed an association study using data 
from the Rotterdam Study, which is presented in chapter 3.2. In a  
combined functional and population based approach, we showed evidence 
for an interaction between smoking and the D allele on IMT. Further,  
in chapter 3.3, we present the association between the ACE I/D and  
measurements of arterial stiffness in the same population. This study shows 
that there is a positive relation between the D allele and carotid stiffness.
In chapter 4, associations between the ACE I/D and clinical outcomes 
are detailed. We investigated the relationship between the I/D  
polymorphism and morbidity and mortality due to cardiovascular diseases 
in chapter 4.1. Although there is no significant association between the 
polymorphism and cardiovascular morbidity, carriers of the DD genotype 
show an increased risk of mortality as a result of cardiovascular diseases 
among current smokers. This association is mainly present in younger age 
groups. In addition, we used total mortality as the outcome of interest and 
observed the same finding among smokers at younger ages. We present 
these results in chapter 4.2. A methodological study is presented in chapter 
4.3 using the inverse probability of censoring weighted analyses to  
investigate a possible co-morbidity effect. The plausibility of selective 
censoring by cardiovascular mortality is tested in regard to the association 
between the ACE I/D and Alzheimer’s disease. The standard and corrected 
analyses show no differences, suggesting that a co-morbidity effect is not 
playing a role in that association. 
Finally, chapter 5 provides a general discussion on the ACE gene, the 
linkage between the I/D and other polymorphisms in this gene, the  
relationship between the I/D and other complex diseases, some  
methodological aspects, and ideas for the future studies.
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Samenvatting (summary in Dutch)
Atherosclerose, een progressieve aandoening van de grote arteriën, is de 
belangrijkste factor in de pathofysiologie van cardiovasculaire ziekten.  
Ongeveer de helft van alle sterfte in de Westerse wereld is het gevolg van 
deze ziekten. Het identificeren van de risico factoren betrokken bij het 
ontstaan en de progressie van atherosclerose, zou uiteindelijk kunnen leiden 
tot een beter inzicht in de pathofysiologie van deze aandoening, waardoor 
betere behandeling en preventie mogelijk worden. In de laatste 50 jaar  
hebben veel epidemiologische studies een poging gedaan de risico factoren 
voor atherosclerose op te sporen. Vele factoren zijn ontdekt, waaronder pure  
omgevingsfactoren, maar ook factoren met een belangrijke genetische  
component. In dit proefschrift hebben we de genetische basis van  
atherosclerose onderzocht, voornamelijk door ons te richten op één zeer 
bekend genetische polymorphisme, het angiotensin converting enzyme 
insertie/deletie (ACE I/D) polymorphisme. 
Hoofdstuk 1 is een algemene introductie over de bekende aspecten van 
atherosclerose en de verschillende soorten metingen die in dit proefschrift 
gebruikt zijn. Het concept van de genetica in atherosclerose wordt besproken  
en algemene informatie over het ACE I/D polymorphisme wordt gegeven. 
In hoofdstuk 2 hebben we de erfelijkheid berekend van verschillende 
maten van vaatwandstructuur en -functie, waarmee we laten zien in  
hoeverre genetische factoren hierin een rol spelen. Wij gebruikten de  
carotid-femoral pulse wave velocity (PWV) als een indicator voor  
vaatstijfheid en intima media thickness (IMT) van de carotiden en plaque 
score als indicatoren voor atherosclerose. De analyses werden uitgevoerd 
in deelnemers aan de Erasmus Rucphen Familieonderzoek (ERF). Dit is 
een studie uitgevoerd onder 2500 deelnemers, woonachtig in een genetisch 
geïsoleerd gebied in het Zuidwesten van Nederland, die allen deel uitmaken 
van één grote stamboom. Deze stamboom is niet geselecteerd op basis van 
een ziekte. De uitkomsten in hoofdstuk 2 zijn de eerste resultaten van de 
ERF studie, waarbij data van 930 deelnemers gebruikt is, welke  
beschikbaar waren op het moment van de analyses. De erfelijkheid van 
PWV, IMT en plaque score wordt gepresenteerd. De voor leeftijd en 
geslacht gecorrigeerde schatting van de erfelijkheid was 0.36 voor PWV, 
0.41 voor carotid IMT en 0.28 voor plaque score. Na correctie voor andere 
risico factoren waren deze schattingen 0.26, 0.35 en 0.21 voor respectievelijk 
PWV, IMT en plaque score. Alle schattingen waren statistisch significant. 
Voor zover ons bekend, is dit het enige verslag van de erfelijkheid van 
PWV, welke in grote mate gelijk is aan de schattingen van de erfelijkheid 
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van IMT en plaque score in onze studie. Deze bevinding suggereert dat 
het zoeken naar genen verantwoordelijk voor vaatstijfheid van even grote 
waarde kan zijn als het zoeken naar genen voor atherosclerose.  
Hoofdstuk 3 beschrijft studies over het ACE I/D polymorphisme en 
atherosclerose metingen. Eerdere gepubliceerde studies over de relatie  
tussen ACE I/D en IMT van de carotiden lieten inconsistente resultaten 
zien. In hoofdstuk 3.1 presenteren we een meta-analyse die al deze resultaten 
combineert. Gebaseerd op dit resultaat blijkt er een sterkere associatie te 
bestaan in de zogenaamde “hoge-risico” populaties. Uitgaande van deze 
bevinding hebben we een associatie studie gedaan met data van de Rotterdam 
Studie, welke beschreven staat in hoofdstuk 3.2. In een gecombineerd  
functioneel en populatie onderzoek, vonden we aanwijzingen voor  
interactie tussen roken en het D allel op IMT. Verder presenteren we 
in hoofdstuk 3.3 de associatie tussen het ACE I/D polymorphisme en 
metingen van vaatstijfheid in dezelfde populatie. Deze studie laat zien dat 
er een positieve relatie is tussen het D allel en vaatstijfheid.
In hoofdstuk 4 beschrijven we de associaties tussen het ACE I/D  
polymorphisme en klinische gevolgen. We onderzochten in hoofdstuk 4.1 
de relatie tussen ACE I/D, morbiditeit en mortaliteit als gevolg van  
cardiovasculaire ziekten . Er was geen significante associatie tussen het  
polymorphisme en cardiovasculaire morbiditeit, echter, onder rokers 
vonden wij dat personen met het DD genotype een verhoogd risico hebben 
op sterfte als gevolg van cardiovasculaire ziekten. Deze associatie was  
voornamelijk aanwezig in de jongere leeftijdsgroep. Verder vonden we 
dezelfde associatie wanneer we onder jonge rokers de totale sterfte als  
eindpunt namen. Deze resultaten presenteren wij in hoofdstuk 4.2. In 
hoofdstuk 4.3 beschrijven we een methodologische studie waarin we  
gebruik maakten van de “inverse probability of censoring weighted  
analyses” om het effect van co-morbiditeit te onderzoeken. De mogelijkheid  
van selectieve censoring bij cardiovasculaire sterfte werd getest met betrekking 
tot de associatie tussen ACE I/D en de ziekte van Alzheimer. De standaard 
en gecorrigeerde analyses lieten geen verschil zien, wat suggereert dat het 
effect van co-morbiditeit geen rol speelt in deze associatie. 
Tenslotte beschrijft hoofdstuk 5 een algemene discussie over het ACE 
gen, linkage met andere polymorphismen en het I/D polymorphisme in dit 
gen, de relatie tussen het I/D polymorphisme en andere complexe ziekten 
en een aantal methodologische aspecten en ideeën voor toekomstige studies.
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»��� �� «���� �������� ��� ��� ���  � ������IMT���� ����  . ��� ����� ���� � �����
������ �� �������Rotterdam Study������ ���� �� �� ����� ����� �� ���-���  ��
��� ��� ���� .��� ��� ����� �� ������ ������ ���D�� ��ACE�� ����� ���� �
������� ���IMT�� ���� ��  ��� .��� �� ��� �� ����-���� ����� �ACE I/D�
��������������� ���� �� ����� ������� �� ���� ��� ����� ������ ����� ���� ��
������ ����� �� ������ ���D���� ���� ������� �� ���� � .
��� ������ ����� �ACE I/D����� �  ��� ��� ����� ������ ��� .��� �����
���  ������I/D������� �� ������ � ������� �� ���� � ��� ����-���� �����
��� .���� ����� ��� �������� ��� ������� ���� �� ���� � ������������ ���� �  ��� ��
������ �� ����� ������ �����DD������ �� ������ �� ������� ����� ��  � ��� ���
�� ���� �� �������� .���� ��� ���� �� ����� ����� ����� ���� ����� . ������ ��
��� �� �� ����� ���� � ������ ��� �� ��� ����� �� �� ��� ��� � ��� ����������
���� ����� ���� �� ����������� ������ �� .��� �� ����� ����-���� ��� ����� . ��
��� �� ������� �� ���������� ������inverse probability of censoring weighted 
analyses��� �� ������ �� �� ������ ����� ��� ����� �����-���� ��� ����� . ��
� ���� ��������� �� ������ ���� �� ������� ��� ��� ��������� �� �� ���� � ��� ���
���ACE I/D���� ����� ������� ������ ���� .��������� �� ���� ����� ������� ��� ��
���� ������ ����� ��� �� ���� ��� �� ������� ���� �� ������ ��� ��� ����� � ���������
��� ����� ��I/D��� ���� ������� ���� .
��� ������ ����� ������ ������ �� ��� ����� ��� ��ACE�� �� �
(linkage)���I/D��� �  ��������� ����� ��� ��� �� ���� ���I/D������ ���� �   ���
���� � ����������� ���� ����� ���� �� ����� ������� ������ ������� .
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������ �� � �� ������(atherosclerosis)�� �������� ����� �������  ���
� ��� ��� ���������� ������������� �� ��� ����� �� ������� �� ���� � ��� ���
����� .������ ��� ����� �� ���� ����� �� ��� � ��� �� ���� ������ ����� ������ .
� ����� ��������� ���� ��� �� ������� ����� ���� ������ ������ � ����� �� ������ �
��� ����� ����� �� � �������� ��� �� ������ �� ������� ���� ���� .�� �������
���� ��� ������������ ������� �� ������ �������� ������ �� ���� ����� �� ���
���� ������� .��� �� ��������� ������ ������ ��������:� ��� ���� �� ���������
����� ������ ���� ���� ���� � ����� .����� ��� ���� ������ ������ ���� �� ����
���� ������������ �� ��� ��� �� ����� ������� ������ ������� ��� ��
insertion/deletion (I/D)  �� ��angiotensin converting enzyme (ACE) .
���������  ������ ����� �� ����� �� ���� ������ �� ����� ���� ������ ��� ��
��������� ���� �� ������ �������� ��� �� ������ ������� ���� ��� �� ���� . ��� �����
��� ������ ��� ������� � ��� ���� �� �� ������ �� �����ACE I/D����  ���
��� .
��� �������� ������  �� ������ ����� �� ������ ���� ���� ��� ����� �����
��� � ����������������� ����� �� .��� ��� ���� ���� �� �������  ������� ���
���� �(Pulse wave velocity, PWV)����� ���� �� ����� ����� ��(arterial
stiffness)  ����� �� �������������������(intima media thickness, IMT) ��
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�����(isolated population)������ �� �� ����� ���� ���� ��Erasmus Rucphen 
Family (ERF)���� ����  ��� ����� ����� ���� .������ERF����� ��� �� ����� ��
�� ��������� ���� �� ����� ����� ��� �� ������ .�� �� �� ���� ����� ���
���� ������ ���� ������ ���� �� ������� � ����� ���� ���������� .��� �� �� ������
������� �� ����� ����� ���� �����ERF���� �� �� ���� ������ ������������
�� ����������� ����� ����� ����� ����� �� ����� ��� ����� ���� �� �� ��� . ���
����� ������ ���� �������� ����� �����PWV�IMT���� �  �� ������� ������ .
����� ���������� � �� ���� ��� ����� ������������PWV��������IMT� �
������ ����  ������� ������� � .��� ������ ���� ����� ���� ���� ����� �� ���
���� ����� �����PWV�IMT��� � ��� ����� ����� ����� �� ������� �������
���� ���� .����� ������ ��������� ����� ��� �� �����  �������� .�� �� ������ ��
����� �� ����� ����� ��� ������ ����  �����PWV������ �� ������ ��� �� �� ����
�����  �����IMT��� �  ��� ����� ����� ������� ��� .����� ����� ��� ���� ��� �� ��
�� ���� ������� ����� ���� �� ���� ����� ���� ����� ������ �� �����  �������
���� ������� ������ �� .
������� ��� ���� �� �������� ����  ������ACE I/D������ ��� ��  ����  ���
��� ������ �� ����� .�� ����� �������ACE I/D������� �IMT� �� ��  �����
�������� ��������� ������ ��� .��� ���-����� ����� ��������� �� ��  �� �����������
�� ����� �� �� �� ���� ���������� . ���� ������������ �� ������� �������� �� ���
(summary in Persian)
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